<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Med Insights Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Med Insights Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">Clinical Medicine Insights: Pediatrics</journal-id>
<journal-title-group>
<journal-title>Clinical Medicine Insights. Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">1179-5565</issn>
<publisher>
<publisher-name>Libertas Academica</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27330338</article-id>
<article-id pub-id-type="pmc">4910649</article-id>
<article-id pub-id-type="doi">10.4137/CMPed.S38337</article-id>
<article-id pub-id-type="publisher-id">cmped-10-2016-043</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Frye</surname>
<given-names>Richard E.</given-names>
</name>
<xref ref-type="aff" rid="af1-cmped-10-2016-043">1</xref>
<xref ref-type="aff" rid="af2-cmped-10-2016-043">2</xref>
<xref ref-type="corresp" rid="c1-cmped-10-2016-043"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rossignol</surname>
<given-names>Daniel A.</given-names>
</name>
<xref ref-type="aff" rid="af3-cmped-10-2016-043">3</xref>
</contrib>
</contrib-group>
<aff id="af1-cmped-10-2016-043"><label>1</label>Arkansas Children’s Research Institute, Little Rock, AR, USA.</aff>
<aff id="af2-cmped-10-2016-043"><label>2</label>Division of Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</aff>
<aff id="af3-cmped-10-2016-043"><label>3</label>Rossignol Medical Center, Irvine CA, USA.</aff>
<author-notes>
<corresp id="c1-cmped-10-2016-043">CORRESPONDENCE: <email>REFrye@uams.edu</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>10</volume>
<fpage>43</fpage>
<lpage>56</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>3</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access">
<license-p>This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.</license-p>
</license>
</permissions>
<abstract>
<p>Despite the fact that the prevalence of autism spectrum disorder (ASD) continues to rise, no effective medical treatments have become standard of care. In this paper we review some of the pathophysiological abnormalities associated with ASD and their potential associated treatments. Overall, there is evidence for some children with ASD being affected by seizure and epilepsy, neurotransmitter dysfunction, sleep disorders, metabolic abnormalities, including abnormalities in folate, cobalamin, tetrahydrobiopterin, carnitine, redox and mitochondrial metabolism, and immune and gastrointestinal disorders. Although evidence for an association between these pathophysiological abnormalities and ASD exists, the exact relationship to the etiology of ASD and its associated symptoms remains to be further defined in many cases. Despite these limitations, treatments targeting some of these pathophysiological abnormalities have been studied in some cases with high-quality studies, whereas treatments for other pathophysiological abnormalities have not been well studied in many cases. There are some areas of more promising treatments specific for ASD including neurotransmitter abnormalities, particularly imbalances in glutamate and acetylcholine, sleep onset disorder (with behavioral therapy and melatonin), and metabolic abnormalities in folate, cobalamin, tetrahydrobiopterin, carnitine, and redox pathways. There is some evidence for treatments of epilepsy and seizures, mitochondrial and immune disorders, and gastrointestinal abnormalities, particularly imbalances in the enteric microbiome, but further clinical studies are needed in these areas to better define treatments specific to children with ASD. Clearly, there are some promising areas of ASD research that could lead to novel treatments that could become standard of care in the future, but more research is needed to better define subgroups of children with ASD who are affected by specific pathophysiological abnormalities and the optimal treatments for these abnormalities.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorders</kwd>
<kwd>carnitine</kwd>
<kwd>cobalamin</kwd>
<kwd>epilepsy</kwd>
<kwd>folate</kwd>
<kwd>genetic disorders</kwd>
<kwd>mitochondrial dysfunction</kwd>
<kwd>review</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Autism spectrum disorder (ASD) is behaviorally defined but is associated with significant pathophysiology.<xref ref-type="bibr" rid="b1-cmped-10-2016-043">1</xref> ASD is estimated to affect 1 in 45 individuals in the United States<xref ref-type="bibr" rid="b2-cmped-10-2016-043">2</xref> with a dramatic increase in prevalence over the past two decades. Although significant debate surrounds the reasons for this increase, the fact remains that approximately 2% of children are affected. Although standard of care behavioral therapy can be helpful, to be optimally effective, behavioral therapy requires full-time engagement of a one-on-one therapist over many years, but outcomes are suboptimal in many cases. Recent reviews have pointed out that controlled studies are lacking on behavioral therapies.<xref ref-type="bibr" rid="b3-cmped-10-2016-043">3</xref> Thus, medical therapies that can augment the effects of behavioral therapy are urgently needed.</p>
<p>A majority of ASD research have focused on the genetic causes of ASD.<xref ref-type="bibr" rid="b1-cmped-10-2016-043">1</xref> This has been driven by the fact that ASD appears to have a highly heritable component. However, despite the apparent heritability, inherited single gene and chromosomal defects only account for a minority of ASD cases.<xref ref-type="bibr" rid="b4-cmped-10-2016-043">4</xref> Other studies have demonstrated that ASD cases may be associated with mutations that affect neuronal function. However, for the most part, these mutations are rare de novo mutations, suggesting that they are acquired, not inherited, mutations that have probably resulted secondary to errors in DNA maintenance and/or the result of DNA damage due to exposure to extrinsic and/or intrinsic stressors.<xref ref-type="bibr" rid="b5-cmped-10-2016-043">5</xref>,<xref ref-type="bibr" rid="b6-cmped-10-2016-043">6</xref> These findings indicate that the etiology of ASD is complex and that the heritability component may not be fully accounted for by genetics.<xref ref-type="bibr" rid="b7-cmped-10-2016-043">7</xref>,<xref ref-type="bibr" rid="b8-cmped-10-2016-043">8</xref> For example, one common factor shared with siblings is the prenatal maternal environment, which is increasingly being recognized as important for developmental outcomes.<xref ref-type="bibr" rid="b9-cmped-10-2016-043">9</xref></p>
<p>It is becoming clear that ASD arises from complicated interactions between genetic predisposition and environmental factors,<xref ref-type="bibr" rid="b10-cmped-10-2016-043">10</xref>,<xref ref-type="bibr" rid="b11-cmped-10-2016-043">11</xref> and that there are numerous environmental agents that may be involved in the etiology of ASD.<xref ref-type="bibr" rid="b12-cmped-10-2016-043">12</xref> In fact, genome-wide searches across large sample sizes have primarily identified rare de novo mutations in ASD, thereby pointing toward acquired mutations that could be the result of environmental factors.<xref ref-type="bibr" rid="b5-cmped-10-2016-043">5</xref>,<xref ref-type="bibr" rid="b6-cmped-10-2016-043">6</xref> Since genetic defects cannot be readily treated, we have concentrated on the pathophysiological abnormalities associated with ASD that may be amendable to medical intervention. Recent studies have associated impairments in basic physiological processes such as redox<xref ref-type="bibr" rid="b13-cmped-10-2016-043">13</xref> and mitochondrial<xref ref-type="bibr" rid="b1-cmped-10-2016-043">1</xref>,<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref>,<xref ref-type="bibr" rid="b15-cmped-10-2016-043">15</xref> metabolism, essential metabolites such as folate,<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref> tetrahydrobiopterin<xref ref-type="bibr" rid="b17-cmped-10-2016-043">17</xref>–<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref> and carnitine,<xref ref-type="bibr" rid="b20-cmped-10-2016-043">20</xref>–<xref ref-type="bibr" rid="b23-cmped-10-2016-043">23</xref> and immune dysfunction.<xref ref-type="bibr" rid="b1-cmped-10-2016-043">1</xref> Interestingly, several of these physiological abnormalities are also observed in genetic syndromes associated with ASD such as Rett syndrome,<xref ref-type="bibr" rid="b24-cmped-10-2016-043">24</xref>–<xref ref-type="bibr" rid="b26-cmped-10-2016-043">26</xref> PTEN mutations,<xref ref-type="bibr" rid="b27-cmped-10-2016-043">27</xref> Phelan-McDermid syndrome,<xref ref-type="bibr" rid="b28-cmped-10-2016-043">28</xref>,<xref ref-type="bibr" rid="b29-cmped-10-2016-043">29</xref> 15q11-q13 duplication syndrome,<xref ref-type="bibr" rid="b30-cmped-10-2016-043">30</xref>,<xref ref-type="bibr" rid="b31-cmped-10-2016-043">31</xref> Angelman syndrome,<xref ref-type="bibr" rid="b32-cmped-10-2016-043">32</xref> Septo-optic dysplasia,<xref ref-type="bibr" rid="b33-cmped-10-2016-043">33</xref> and Down syndrome.<xref ref-type="bibr" rid="b34-cmped-10-2016-043">34</xref>,<xref ref-type="bibr" rid="b35-cmped-10-2016-043">35</xref></p>
<p>Identification of pathophysiological abnormalities associated with ASD in individual patients can lead to a better understanding of the basic biological dysfunction affecting the individual patient and lead toward an individualized treatment plan. Thus, some of the more common pathophysiological abnormalities associated with ASD are reviewed, followed by a discussion of the evidence for specific targeted treatments that might be effective. Through a comprehensive understanding of the biological underpinnings of an individual with ASD, in the future, it may be possible to formulate a detailed, personalized, and precise treatment plan in order to achieve optimal outcomes.</p>
</sec>
<sec>
<title>Pathophysiology of ASD</title>
<sec>
<title>Seizures and epilepsy</title>
<p>Individuals with ASD have a higher prevalence of epilepsy compared to typically developing individuals,<xref ref-type="bibr" rid="b36-cmped-10-2016-043">36</xref>–<xref ref-type="bibr" rid="b40-cmped-10-2016-043">40</xref> particularly epilepsy that is refractory to standard treatments.<xref ref-type="bibr" rid="b41-cmped-10-2016-043">41</xref>,<xref ref-type="bibr" rid="b42-cmped-10-2016-043">42</xref> Epilepsy is associated with higher rates of intellectual disability,<xref ref-type="bibr" rid="b36-cmped-10-2016-043">36</xref>,<xref ref-type="bibr" rid="b43-cmped-10-2016-043">43</xref> more severe ASD symptoms,<xref ref-type="bibr" rid="b44-cmped-10-2016-043">44</xref> and higher rates of mortality,<xref ref-type="bibr" rid="b45-cmped-10-2016-043">45</xref>,<xref ref-type="bibr" rid="b46-cmped-10-2016-043">46</xref> especially if it continues into adulthood.<xref ref-type="bibr" rid="b39-cmped-10-2016-043">39</xref>,<xref ref-type="bibr" rid="b40-cmped-10-2016-043">40</xref> The underlying causes of epilepsy are often related to underlying genetic<xref ref-type="bibr" rid="b47-cmped-10-2016-043">47</xref>,<xref ref-type="bibr" rid="b48-cmped-10-2016-043">48</xref> and/or metabolic abnormalities.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref>,<xref ref-type="bibr" rid="b49-cmped-10-2016-043">49</xref>,<xref ref-type="bibr" rid="b50-cmped-10-2016-043">50</xref></p>
<p>Particularly novel to children with ASD are subclinical electrical discharges (SEDs) that have a prevalence as high as 61%<xref ref-type="bibr" rid="b51-cmped-10-2016-043">51</xref> and 100%<xref ref-type="bibr" rid="b52-cmped-10-2016-043">52</xref> in studies that have used long-term electroencephalogram monitoring and magnetoencephalography, respectively. Studies have suggested that children with ASD who manifest SEDs have a unique cognitive phenotype.<xref ref-type="bibr" rid="b53-cmped-10-2016-043">53</xref>–<xref ref-type="bibr" rid="b56-cmped-10-2016-043">56</xref> Children with SEDs and ASD appear to be similar to children with epilepsy and ASD in several ways. Both are more likely to experience regression and have an abnormal neurological examination and cerebral lesions as compared to children with ASD without epilepsy.<xref ref-type="bibr" rid="b53-cmped-10-2016-043">53</xref> However, children with epilepsy and ASD are more likely to have intellectual impairment and higher levels of problems with socialization and hyperactivity as compared to children with ASD and SEDs.<xref ref-type="bibr" rid="b54-cmped-10-2016-043">54</xref>,<xref ref-type="bibr" rid="b57-cmped-10-2016-043">57</xref></p>
</sec>
<sec>
<title>Neurotransmitter disorders</title>
<p>Multiple neurotransmitter deficiencies have been reported in ASD. These include monoamine (ie, dopamine, norepinephrine, and serotonin),<xref ref-type="bibr" rid="b17-cmped-10-2016-043">17</xref>–<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref> amino acid [ie, glutamate, gamma-aminobutyric acid (GABA)],<xref ref-type="bibr" rid="b58-cmped-10-2016-043">58</xref>,<xref ref-type="bibr" rid="b59-cmped-10-2016-043">59</xref> and cholinergic (ie, acetylcholine) neurotransmitters.<xref ref-type="bibr" rid="b58-cmped-10-2016-043">58</xref> The etiologies of these neurotransmitter disorders are not always known, but studies using animal models of ASD have pointed to genetic mutations that disrupt neurotransmission.<xref ref-type="bibr" rid="b60-cmped-10-2016-043">60</xref>,<xref ref-type="bibr" rid="b61-cmped-10-2016-043">61</xref> Metabolic disturbances, some of which are reviewed below, can also disrupt neurotransmission production. For example, central deficiencies in cofactors important for the production of monoamine neurotransmitters, such as folate<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref>,<xref ref-type="bibr" rid="b62-cmped-10-2016-043">62</xref> and tetrahydrobiopterin,<xref ref-type="bibr" rid="b17-cmped-10-2016-043">17</xref>–<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref> could disrupt monoamine neurotransmitter production. Abnormalities in redox metabolism found in the brain of children with ASD<xref ref-type="bibr" rid="b63-cmped-10-2016-043">63</xref>,<xref ref-type="bibr" rid="b64-cmped-10-2016-043">64</xref> can disrupt glutamate metabolism.<xref ref-type="bibr" rid="b13-cmped-10-2016-043">13</xref>,<xref ref-type="bibr" rid="b65-cmped-10-2016-043">65</xref> In addition, specific metabolic disorders associated with ASD can directly disrupt neurotransmitter function. For example, succinic semialdehyde dehydrogenase deficiency directly affects GABA,<xref ref-type="bibr" rid="b49-cmped-10-2016-043">49</xref> and mitochondrial disorders can influence both GABA and acetylcholine neurotransmission.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> One neurotransmitter that is becoming increasing recognized to have a role in ASD is oxytocin, particularly in its role in social impairments.<xref ref-type="bibr" rid="b66-cmped-10-2016-043">66</xref> In addition, autoantibodies, which are discussed below, are sometime found in children with ASD, which can disrupt neurotransmission function.</p>
</sec>
<sec>
<title>Sleep disorders</title>
<p>Sleep abnormalities associated with ASD are extremely common, and include prolonged sleep onset latency, frequent nighttime awakenings, reduced sleep duration, parasomnias, sleep disordered breathing, and daytime sleepiness.<xref ref-type="bibr" rid="b67-cmped-10-2016-043">67</xref>–<xref ref-type="bibr" rid="b69-cmped-10-2016-043">69</xref> Sleep abnormalities have been associated with reduced daytime functioning, including impaired social interaction, communication, behavior, anxiety, and aggression<xref ref-type="bibr" rid="b68-cmped-10-2016-043">68</xref>–<xref ref-type="bibr" rid="b71-cmped-10-2016-043">71</xref> as well as poor quality of life for the child and their family.<xref ref-type="bibr" rid="b72-cmped-10-2016-043">72</xref></p>
<p>The concentration and circadian rhythm of melatonin, the endogenous neurohormone best known for regulating sleep onset, is often disrupted in ASD.<xref ref-type="bibr" rid="b68-cmped-10-2016-043">68</xref>,<xref ref-type="bibr" rid="b69-cmped-10-2016-043">69</xref> 6- Sulfatoxymelatonin, the major metabolite of melatonin, is reduced in some children with ASD suggesting decreased melatonin production<xref ref-type="bibr" rid="b73-cmped-10-2016-043">73</xref>,<xref ref-type="bibr" rid="b74-cmped-10-2016-043">74</xref> and concentrations are inversely correlated with the quantity of deep (non-rapid eye movement) sleep.<xref ref-type="bibr" rid="b75-cmped-10-2016-043">75</xref> A recent study has suggested that the <italic>N</italic>-acetylserotonin, the metabolite preceding melatonin in the biosynthesis pathway, is increased in ASD and inversely correlated with melatonin concentrations.<xref ref-type="bibr" rid="b76-cmped-10-2016-043">76</xref> These findings are consistent with studies that demonstrate that polymorphisms in acetylserotonin methyltransferase, the enzyme that converts <italic>N</italic>-acetylserotonin to melatonin, are associated with disrupted circadian melatonin rhythms and lower melatonin concentrations in children with ASD and the parent(s) from which the polymorphism was inherited.<xref ref-type="bibr" rid="b77-cmped-10-2016-043">77</xref> Thus, data seem to point to metabolic abnormalities in melatonin synthesis underlying some of the sleep problems associated with ASD.</p>
</sec>
<sec>
<title>Metabolic disorders</title>
<p>Several metabolic disorders have been described in individuals with ASD with many having associated treatments. <xref ref-type="bibr" rid="b13-cmped-10-2016-043">13</xref>,<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref>,<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref>,<xref ref-type="bibr" rid="b49-cmped-10-2016-043">49</xref>,<xref ref-type="bibr" rid="b50-cmped-10-2016-043">50</xref>,<xref ref-type="bibr" rid="b62-cmped-10-2016-043">62</xref>,<xref ref-type="bibr" rid="b78-cmped-10-2016-043">78</xref> Below we review some of the metabolic disorders that appear to affect at least a significant portion of children with ASD.</p>
<sec>
<title>Folate metabolism</title>
<p>Folate is essential for many metabolic processes, including redox metabolism and methylation.<xref ref-type="bibr" rid="b79-cmped-10-2016-043">79</xref> ASD has been associated with polymorphisms that can decrease the production of 5-methyltetrahydrofolate and/or impair folate transport across the blood–brain barrier and into neurons. Polymorphisms associated with ASD have been found in genes that code for methylenetetrahydrofolate reductase,<xref ref-type="bibr" rid="b80-cmped-10-2016-043">80</xref>–<xref ref-type="bibr" rid="b89-cmped-10-2016-043">89</xref> dihydrofolate reductase,<xref ref-type="bibr" rid="b90-cmped-10-2016-043">90</xref> and the reduced folate carrier.<xref ref-type="bibr" rid="b88-cmped-10-2016-043">88</xref> Also significant is the impairment in folate transport across the blood–brain barrier due to dysfunction of the folate receptor alpha (FRα).<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref> FRα dysfunction can be caused by autoantibodies and by mitochondrial dysfunction.<xref ref-type="bibr" rid="b91-cmped-10-2016-043">91</xref> ASD is associated with a high prevalence of FRα autoantibodies<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref>,<xref ref-type="bibr" rid="b92-cmped-10-2016-043">92</xref> and mitochondrial dysfunction.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref>,<xref ref-type="bibr" rid="b15-cmped-10-2016-043">15</xref> Dysfunction of the FRα, when severe, causes cerebral folate deficiency, a disorder that causes epilepsy, neurodevelopmental regression, autism, and neurological abnormalities such as spasticity and movement disorders.<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref>,<xref ref-type="bibr" rid="b92-cmped-10-2016-043">92</xref>–<xref ref-type="bibr" rid="b95-cmped-10-2016-043">95</xref> Although the FRα autoantibodies are not believed to cause mitochondrial dysfunction, folate is integral for mitochondrial function.<xref ref-type="bibr" rid="b96-cmped-10-2016-043">96</xref> Thus, reduced folate availability in the brain could result in central nervous system (CNS) mitochondrial dysfunction.</p>
</sec>
<sec>
<title>Cobalamin metabolism</title>
<p>Abnormalities in cobalamin-dependent metabolism have been associated with ASD,<xref ref-type="bibr" rid="b88-cmped-10-2016-043">88</xref> although blood cobalamin concentrations have been inconsistently reported to be both decreased and increased in the ASD population.<xref ref-type="bibr" rid="b80-cmped-10-2016-043">80</xref> However, a recent study reported lower cobalamin concentrations in postmortem brain samples from individuals with ASD compared to controls, suggesting that a cerebral cobalamin deficit is associated with ASD.<xref ref-type="bibr" rid="b97-cmped-10-2016-043">97</xref> Metabolites in the methylation and glutathione pathways that are partially dependent on cobalamin, such as methionine, homocysteine, and cysteine, have been reported to be abnormal in some children with ASD.<xref ref-type="bibr" rid="b80-cmped-10-2016-043">80</xref> In addition, studies have pointed to polymorphism in cobalamin-associated genes including genes that code for methionine synthase, a cobalamin-dependent enzyme, and transcobalamin, the cobalamin transporter.<xref ref-type="bibr" rid="b88-cmped-10-2016-043">88</xref> In one recent study, methionine synthase activity was significantly lower in brain samples from individuals with autism compared to age-matched controls.<xref ref-type="bibr" rid="b97-cmped-10-2016-043">97</xref></p>
</sec>
<sec>
<title>Tetrahydrobiopterin metabolism</title>
<p>Tetrahydrobiopterin (BH<sub>4</sub>) is a naturally occurring molecule that is essential for critical metabolic pathways, including those responsible for the production of monoamine neurotransmitters, the breakdown of phenylalanine, and the production of nitric oxide.<xref ref-type="bibr" rid="b18-cmped-10-2016-043">18</xref> BH<sub>4</sub> is readily oxidized by reactive species, leading to its destruction when oxidative stress is prominent, such as in ASD.<xref ref-type="bibr" rid="b17-cmped-10-2016-043">17</xref> The cerebrospinal fluid concentration of BH<sub>4</sub> has been reported to be depressed in some individuals with ASD.<xref ref-type="bibr" rid="b17-cmped-10-2016-043">17</xref>,<xref ref-type="bibr" rid="b18-cmped-10-2016-043">18</xref> Thus, decreased CNS BH<sub>4</sub> concentrations could account for CNS monoamine neurotransmitter and nitric oxide disturbances associated with ASD.</p>
</sec>
<sec>
<title>Carnitine metabolism</title>
<p>Carnitine deficiency may be common in ASD but those children with ASD and carnitine deficiency have not been well characterized.<xref ref-type="bibr" rid="b22-cmped-10-2016-043">22</xref> Recently, a defect in the TMLHE gene, a gene that codes for the first enzyme in the carnitine biosynthesis pathway, was reported in seven children with ASD.<xref ref-type="bibr" rid="b23-cmped-10-2016-043">23</xref> This genetic defect was more common in probands from male–male multiplex ASD families but was not more common in ASD children overall, suggesting that this was not a causative mutation but a factor that interacts with other genetic and/or environmental factors. Disorders of fatty acid metabolism, which may involve carnitine metabolism, have also been reported in individuals with ASD.<xref ref-type="bibr" rid="b21-cmped-10-2016-043">21</xref>,<xref ref-type="bibr" rid="b98-cmped-10-2016-043">98</xref> Carnitine metabolism is important in the transportation of short-chain fatty acids produced by the microbiome, so a deficiency in carnitine could result from imbalances in the interactions between the host and the enteric microbiome.<xref ref-type="bibr" rid="b21-cmped-10-2016-043">21</xref>,<xref ref-type="bibr" rid="b99-cmped-10-2016-043">99</xref> Given that mitochondrial disease (MD) and dysfunction can disrupt carnitine metabolism, carnitine deficiency could also be secondary to mitochondrial dysfunction.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref>,<xref ref-type="bibr" rid="b100-cmped-10-2016-043">100</xref></p>
</sec>
<sec>
<title>Redox metabolism</title>
<p>Several lines of evidence support the notion that some children with ASD have abnormal redox metabolism.<xref ref-type="bibr" rid="b13-cmped-10-2016-043">13</xref>,<xref ref-type="bibr" rid="b64-cmped-10-2016-043">64</xref>,<xref ref-type="bibr" rid="b80-cmped-10-2016-043">80</xref> Several case–control studies report abnormal glutathione metabolism in plasma,<xref ref-type="bibr" rid="b101-cmped-10-2016-043">101</xref>–<xref ref-type="bibr" rid="b103-cmped-10-2016-043">103</xref> peripheral immune cells,<xref ref-type="bibr" rid="b101-cmped-10-2016-043">101</xref> lymphoblastoid cell lines,<xref ref-type="bibr" rid="b104-cmped-10-2016-043">104</xref>,<xref ref-type="bibr" rid="b105-cmped-10-2016-043">105</xref> mitochondria,<xref ref-type="bibr" rid="b105-cmped-10-2016-043">105</xref> and brain tissue<xref ref-type="bibr" rid="b63-cmped-10-2016-043">63</xref> derived from children with ASD. Oxidative damage to proteins has been documented in the brain,<xref ref-type="bibr" rid="b63-cmped-10-2016-043">63</xref>,<xref ref-type="bibr" rid="b64-cmped-10-2016-043">64</xref> plasma,<xref ref-type="bibr" rid="b102-cmped-10-2016-043">102</xref>,<xref ref-type="bibr" rid="b106-cmped-10-2016-043">106</xref> and lymphoblastoid cell lines,<xref ref-type="bibr" rid="b104-cmped-10-2016-043">104</xref> and oxidative damage to DNA has been found in the plasma<xref ref-type="bibr" rid="b102-cmped-10-2016-043">102</xref> derived from children with ASD. Interestingly, redox abnormalities have been linked to mitochondrial dysfunction in children with ASD in plasma<xref ref-type="bibr" rid="b21-cmped-10-2016-043">21</xref>,<xref ref-type="bibr" rid="b106-cmped-10-2016-043">106</xref> and brain<xref ref-type="bibr" rid="b63-cmped-10-2016-043">63</xref> samples and lymphoblastoid cell lines.<xref ref-type="bibr" rid="b104-cmped-10-2016-043">104</xref>,<xref ref-type="bibr" rid="b107-cmped-10-2016-043">107</xref>,<xref ref-type="bibr" rid="b108-cmped-10-2016-043">108</xref></p>
</sec>
<sec>
<title>Mitochondrial metabolism</title>
<p>Mitochondrial dysfunction is one of the most prevalent metabolic disorders in ASD.<xref ref-type="bibr" rid="b109-cmped-10-2016-043">109</xref> One of the original descriptions of a MD in ASD associated it with epilepsy in the so-called hypotonia, epilepsy, autism and developmental delay (HEADD) syndrome.<xref ref-type="bibr" rid="b110-cmped-10-2016-043">110</xref> Since that time, multiple case series and case reports have described individuals with ASD and MD,<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> and one population-based study estimated the prevalence of classical MD in children with ASD at 7.2%<xref ref-type="bibr" rid="b111-cmped-10-2016-043">111</xref> while a meta-analysis found it closer to 5.0%.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> While only about 5% of children with ASD meet strict criteria for a diagnosis of classical MD, over 30% demonstrate abnormal biomarkers of classical MD,<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> suggesting that criteria designed to diagnose classical MD may be too narrow to diagnose mitochondrial dysfunction in children with ASD.<xref ref-type="bibr" rid="b15-cmped-10-2016-043">15</xref></p>
<p>Some studies suggest that children with ASD may manifest unique biomarkers of mitochondrial dysfunction that are not always considered in the classical definition.<xref ref-type="bibr" rid="b21-cmped-10-2016-043">21</xref>,<xref ref-type="bibr" rid="b112-cmped-10-2016-043">112</xref>,<xref ref-type="bibr" rid="b113-cmped-10-2016-043">113</xref> In support of this high prevalence of mitochondrial dysfunction in ASD are two studies that found lower than normal electron transport chain function in immune cells from 80% of the children with ASD examined.<xref ref-type="bibr" rid="b114-cmped-10-2016-043">114</xref>,<xref ref-type="bibr" rid="b115-cmped-10-2016-043">115</xref></p>
<p>Moreover, there appears to be unique types of mitochondrial dysfunction associated with ASD. Several studies have demonstrated markedly greater than normal activity of complex I in muscle<xref ref-type="bibr" rid="b116-cmped-10-2016-043">116</xref> and complex IV in muscle,<xref ref-type="bibr" rid="b91-cmped-10-2016-043">91</xref>,<xref ref-type="bibr" rid="b117-cmped-10-2016-043">117</xref> skin,<xref ref-type="bibr" rid="b21-cmped-10-2016-043">21</xref> and brain<xref ref-type="bibr" rid="b118-cmped-10-2016-043">118</xref> in children with ASD, and other studies have shown that lymphoblastoid cell lines derived from children with ASD demonstrated elevated respiratory activity as compared to controls.<xref ref-type="bibr" rid="b104-cmped-10-2016-043">104</xref>,<xref ref-type="bibr" rid="b107-cmped-10-2016-043">107</xref>,<xref ref-type="bibr" rid="b108-cmped-10-2016-043">108</xref> This increase in mitochondrial function as measured in these studies may reflect a type of compensation for a yet to be defined mitochondrial problem.</p>
</sec>
<sec>
<title>Cholesterol metabolism</title>
<p>Reports have suggested that children with ASD may have lower cholesterol levels than non-ASD children,<xref ref-type="bibr" rid="b119-cmped-10-2016-043">119</xref> although other studies have not been able to verify this finding,<xref ref-type="bibr" rid="b120-cmped-10-2016-043">120</xref> and another study suggested that lower cholesterol levels were isolated to the high-density lipoprotein fraction.<xref ref-type="bibr" rid="b121-cmped-10-2016-043">121</xref> The interest in cholesterol in ASD is related to a congenital metabolic disorder known as Smith-Lemli-Opitz syndrome in which 50%–75% of these patients manifest ASD symptoms.<xref ref-type="bibr" rid="b122-cmped-10-2016-043">122</xref>,<xref ref-type="bibr" rid="b123-cmped-10-2016-043">123</xref> In this disorder, cholesterol production in blocked at the enzyme Δ-7-dehydrocholesterol reductase, resulting in reduced cholesterol and increased 7-dehydrocholesterol blood concentrations. However, even in the study in which children with ASD were found to have decreased cholesterol levels, the ASD children did not have an elevation in 7-dehydrocholesterol.<xref ref-type="bibr" rid="b119-cmped-10-2016-043">119</xref></p>
</sec>
</sec>
<sec>
<title>Immune disorders</title>
<p>There are multiple lines of evidence, suggesting that the immune system is involved in ASD. For example, classical animal models of ASD use prenatal exposure to lipopolysaccharide that induces a maternal immune response.<xref ref-type="bibr" rid="b124-cmped-10-2016-043">124</xref>,<xref ref-type="bibr" rid="b125-cmped-10-2016-043">125</xref> One impressive study demonstrated that symptoms could be significantly attenuated in a mouse model of Rett syndrome when the mice underwent bone marrow transplant from a wild mouse.<xref ref-type="bibr" rid="b126-cmped-10-2016-043">126</xref> Here, we will review some of the human studies that point toward evidence of immune abnormalities in ASD.</p>
<sec>
<title>Autoantibodies</title>
<p>Studies have reported various common biomarkers of autoimmunity associated with ASD. Autoantibodies indicative of autoimmunity have been reported, including antinuclear<xref ref-type="bibr" rid="b127-cmped-10-2016-043">127</xref> and antinucleosome<xref ref-type="bibr" rid="b128-cmped-10-2016-043">128</xref> antibodies, and C-reactive protein has been shown to be abnormally elevated and correlated with autism severity.<xref ref-type="bibr" rid="b129-cmped-10-2016-043">129</xref> However, children with ASD appear to have unique autoantibodies, including autoantibodies to brain elements such as myelin basic protein, serotonin receptors, cerebellar tissue and enzymes such as glutamic acid decarboxylase,<xref ref-type="bibr" rid="b130-cmped-10-2016-043">130</xref> and antibodies to mitochondria.<xref ref-type="bibr" rid="b131-cmped-10-2016-043">131</xref> Although the clinical significance of some autoantibodies in ASD is not clear, certain autoantibodies have some evidence for being clinically significant, including the FRα autoantibody<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref> mentioned above and the brain endothelial autoantibody linked to epilepsy.<xref ref-type="bibr" rid="b132-cmped-10-2016-043">132</xref>,<xref ref-type="bibr" rid="b133-cmped-10-2016-043">133</xref> Furthermore, a number of studies have correlated the presence of autoantibodies in ASD individuals with the severity of ASD.<xref ref-type="bibr" rid="b127-cmped-10-2016-043">127</xref>,<xref ref-type="bibr" rid="b134-cmped-10-2016-043">134</xref>–<xref ref-type="bibr" rid="b138-cmped-10-2016-043">138</xref></p>
<p>Recently, the overlap between ASD and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS) and Sydenham chorea has been recognized, leading to the consideration of Sydenham chorea associated and PANDAS-associated auto antibodies in ASD. PANDAS and Sydenham chorea associated autoantibodies can disrupt the function of the CaM kinase II enzyme, a multifunctional enzyme highly concentrated in the brain, which functions to control neurotransmission and neuronal excitability,<xref ref-type="bibr" rid="b139-cmped-10-2016-043">139</xref> and is closely associated with regulation of catecholamine<xref ref-type="bibr" rid="b140-cmped-10-2016-043">140</xref> and glutamate<xref ref-type="bibr" rid="b141-cmped-10-2016-043">141</xref> neurotransmission. Abnormalities in the function of CaM kinase II have been linked to movement disorders and neuropsychiatric disorders in children.<xref ref-type="bibr" rid="b142-cmped-10-2016-043">142</xref>,<xref ref-type="bibr" rid="b143-cmped-10-2016-043">143</xref></p>
<p>Another emerging area of research has identified antibodies to fetal brain in the blood of mothers who have had children with ASD. Specific combinations of these antibodies have high specificity for the development of ASD,<xref ref-type="bibr" rid="b144-cmped-10-2016-043">144</xref> and research has shown that injection of these antibodies into pregnant monkeys results in offspring with ASD-like characteristics and abnormal brain growth.<xref ref-type="bibr" rid="b145-cmped-10-2016-043">145</xref>,<xref ref-type="bibr" rid="b146-cmped-10-2016-043">146</xref> Children exposed to these antibodies in utero appear to have specific characteristics including a more severe behavioral and cognitive phenotype<xref ref-type="bibr" rid="b147-cmped-10-2016-043">147</xref> and brain enlargement.<xref ref-type="bibr" rid="b148-cmped-10-2016-043">148</xref></p>
</sec>
<sec>
<title>Hypogammaglobulinemia</title>
<p>IgG has been reported as both decreased<xref ref-type="bibr" rid="b149-cmped-10-2016-043">149</xref>–<xref ref-type="bibr" rid="b152-cmped-10-2016-043">152</xref> and increased<xref ref-type="bibr" rid="b153-cmped-10-2016-043">153</xref>–<xref ref-type="bibr" rid="b155-cmped-10-2016-043">155</xref> in children with ASD compared to controls. The hypogammaglobulinemia reported in some children with ASD does not seem to be due to B-cell dysfunction.<xref ref-type="bibr" rid="b156-cmped-10-2016-043">156</xref> One study reported that IgG concentrations in ASD children were inversely correlated with the severity of aberrant behavior.<xref ref-type="bibr" rid="b151-cmped-10-2016-043">151</xref> Some studies, using sibling controls, demonstrate higher IgG4 concentrations in ASD children.<xref ref-type="bibr" rid="b154-cmped-10-2016-043">154</xref>,<xref ref-type="bibr" rid="b157-cmped-10-2016-043">157</xref> One study examining newborn blood samples in children later diagnosed with ASD found that low IgG was associated with an increased risk of developing ASD.<xref ref-type="bibr" rid="b158-cmped-10-2016-043">158</xref></p>
</sec>
<sec>
<title>Neuroinflammation</title>
<p>One of the first studies to examine neuroinflammation found microglial and astroglial activation associated with patchy neuronal loss, most prominently in the cerebellum and also in the middle frontal and anterior cingulate gyri, on autopsy.<xref ref-type="bibr" rid="b159-cmped-10-2016-043">159</xref> Other studies have reported microglial activation or more microglia in the dorsolateral prefrontal cortex,<xref ref-type="bibr" rid="b160-cmped-10-2016-043">160</xref> frontoinsular<xref ref-type="bibr" rid="b161-cmped-10-2016-043">161</xref> and multiple brain regions<xref ref-type="bibr" rid="b162-cmped-10-2016-043">162</xref> and another study suggest that microglia had a close proxi mity to neurons in the brain of individuals with ASD.<xref ref-type="bibr" rid="b163-cmped-10-2016-043">163</xref></p>
</sec>
<sec>
<title>Cytokine abnormalities</title>
<p>There have been many reports of abnormal cytokine concentrations in the blood, brain, and cerebrospinal fluid of individuals with ASD. A recent meta-analysis found that interleukin (IL)-1β, IL-6, IL-8, interferon (INF)-λ, and MCP-1 are consistently elevated in children with ASD as compared to healthy controls.<xref ref-type="bibr" rid="b164-cmped-10-2016-043">164</xref> Studies have reported increases in IL-8,<xref ref-type="bibr" rid="b159-cmped-10-2016-043">159</xref>,<xref ref-type="bibr" rid="b165-cmped-10-2016-043">165</xref> INF-λ,<xref ref-type="bibr" rid="b159-cmped-10-2016-043">159</xref>,<xref ref-type="bibr" rid="b165-cmped-10-2016-043">165</xref> monocyte chemotactic protein (MCP)-1,<xref ref-type="bibr" rid="b159-cmped-10-2016-043">159</xref> tumor necrosis factor-α (TNF-α),<xref ref-type="bibr" rid="b165-cmped-10-2016-043">165</xref> IL-6,<xref ref-type="bibr" rid="b165-cmped-10-2016-043">165</xref>,<xref ref-type="bibr" rid="b166-cmped-10-2016-043">166</xref> and granulocyte- macrophage colony-stimulating factor<xref ref-type="bibr" rid="b165-cmped-10-2016-043">165</xref> in the brain tissue of individuals with ASD. Others have suggested that cytokine abnormalities are related to gastrointestinal (GI) symptoms in children with ASD.<xref ref-type="bibr" rid="b167-cmped-10-2016-043">167</xref></p>
</sec>
</sec>
<sec>
<title>GI disorders</title>
<p>A wide range of GI symptoms, which can be debilitating, affect up to 91% of children with ASD.<xref ref-type="bibr" rid="b168-cmped-10-2016-043">168</xref>,<xref ref-type="bibr" rid="b169-cmped-10-2016-043">169</xref> For example, a recent report found that children with ASD were more likely to have constipation, diarrhea, or food allergy and/or intolerance as compared to typically developing children and children with developmental delays without ASD.<xref ref-type="bibr" rid="b170-cmped-10-2016-043">170</xref> Other studies have linked unique abnormalities in GI function with ASD, including abnormal carbohydrate transportation across enterocytes<xref ref-type="bibr" rid="b171-cmped-10-2016-043">171</xref> and nonspecific inflammation.<xref ref-type="bibr" rid="b168-cmped-10-2016-043">168</xref>,<xref ref-type="bibr" rid="b169-cmped-10-2016-043">169</xref></p>
<p>There is a growing body of evidence that the trillions of microbes that inhabit the human digestive tract, known as the enteric microbiome, affect immune and metabolic functions,<xref ref-type="bibr" rid="b172-cmped-10-2016-043">172</xref>,<xref ref-type="bibr" rid="b173-cmped-10-2016-043">173</xref> modulate gene expression,<xref ref-type="bibr" rid="b174-cmped-10-2016-043">174</xref>,<xref ref-type="bibr" rid="b175-cmped-10-2016-043">175</xref> and play an important role in brain and behavioral development.<xref ref-type="bibr" rid="b176-cmped-10-2016-043">176</xref> A landmark mouse study highlighted the potential importance of the microbiome in ASD. In this study, the authors showed that alternation in the enteric microbiome using a probiotic ameliorated ASD-like behaviors.<xref ref-type="bibr" rid="b177-cmped-10-2016-043">177</xref></p>
<p>Several studies suggest that the enteric microbiome is atypical in ASD.<xref ref-type="bibr" rid="b171-cmped-10-2016-043">171</xref>,<xref ref-type="bibr" rid="b178-cmped-10-2016-043">178</xref>–<xref ref-type="bibr" rid="b182-cmped-10-2016-043">182</xref> The enteric microbiome of some children with ASD has decreased species diversity and overrepresentation of particular species, including Clostridial species.<xref ref-type="bibr" rid="b183-cmped-10-2016-043">183</xref>,<xref ref-type="bibr" rid="b184-cmped-10-2016-043">184</xref> Disruption in the enteric microbiome may be particularly associated with children who present with GI symptoms at the time of, or prior to, the onset of ASD symptoms and in those who have regressive-type ASD.<xref ref-type="bibr" rid="b185-cmped-10-2016-043">185</xref>,<xref ref-type="bibr" rid="b186-cmped-10-2016-043">186</xref></p>
<p>Interestingly, a rodent model of ASD has shown that a short-chain fatty acid metabolite known as propionic acid (PPA), which is produced by bacteria that are overrepresented in the enteric microbiome of children with ASD (eg, <italic>Clostridia</italic>, <italic>Bacteroides</italic>, and <italic>Desulfovibrio</italic> species), can cause ASD-like behaviors in rats.<xref ref-type="bibr" rid="b99-cmped-10-2016-043">99</xref>,<xref ref-type="bibr" rid="b125-cmped-10-2016-043">125</xref>,<xref ref-type="bibr" rid="b126-cmped-10-2016-043">126</xref>,<xref ref-type="bibr" rid="b187-cmped-10-2016-043">187</xref>,<xref ref-type="bibr" rid="b188-cmped-10-2016-043">188</xref> Independent studies have reported that 17%–24% of ASD children demonstrated consistent elevations in short and long chain acyl-carnitines<xref ref-type="bibr" rid="b99-cmped-10-2016-043">99</xref>,<xref ref-type="bibr" rid="b189-cmped-10-2016-043">189</xref> which is a unique pattern of biochemical abnormalities reported in the PPA rodent model of ASD.<xref ref-type="bibr" rid="b113-cmped-10-2016-043">113</xref> One study reported an elevated urinary PPA metabolite in children with ASD compared to controls.<xref ref-type="bibr" rid="b190-cmped-10-2016-043">190</xref></p>
</sec>
</sec>
<sec>
<title>Treatments for Disorders Associated with Autism</title>
<sec>
<title>Seizure treatments</title>
<p>Research into the particular treatments that best control seizures in children with ASD is limited. Such information is important since some children with ASD tend to be sensitive to the adverse effects of antiepileptic drugs (AEDs). One study used a national survey to determine which traditional and nontraditional treatments might be most effective and best tolerated in individuals with ASD.<xref ref-type="bibr" rid="b191-cmped-10-2016-043">191</xref> Overall, it was found that four AEDs, valproic acid, lamotrigine, levetiracetam, and ethosuximide, were rated as the most effective and best tolerated, while several non-AED treatments were rated as effective and well-tolerated, including the ketogenic diet, modified Atkin’s diet (MAD) and gluten-free casein-free (GFCF) diet. A recent systematic review found that valproic acid, lamotrigine, and levetiracetam had the most evidence for effectiveness and tolerability in ASD, with valproic acid also having good evidence for also improving core ASD symptoms.<xref ref-type="bibr" rid="b50-cmped-10-2016-043">50</xref> The review also highlighted the evidence for the ketogenic diet and MAD, especially in AED-resistant epilepsy and pointed out that metabolic and genetic disorders that may underlie epilepsy in ASD have targeted treatments that can be effective if such underlining disorders are identified. In addition, intravenous immunoglobulin (IVIG), which can sometime improve ASD-related symptoms, may also be effective in drug-resistant epilepsy.<xref ref-type="bibr" rid="b192-cmped-10-2016-043">192</xref>–<xref ref-type="bibr" rid="b194-cmped-10-2016-043">194</xref></p>
<p>The other issue that is often raised is whether SEDs should be treated in children with ASD. Several case studies<xref ref-type="bibr" rid="b195-cmped-10-2016-043">195</xref>,<xref ref-type="bibr" rid="b196-cmped-10-2016-043">196</xref> and case series<xref ref-type="bibr" rid="b55-cmped-10-2016-043">55</xref> have demonstrated that valproic acid improved core ASD behaviors and language in children with ASD who had SED but no seizures. Other studies have examined the effect of AEDs on children with behavioral problems and epilepsy who manifested SEDs. Two double-blind, placebo controlled (DBPC) trials demonstrated improvements in these children with lamotrigine treatment,<xref ref-type="bibr" rid="b197-cmped-10-2016-043">197</xref>,<xref ref-type="bibr" rid="b198-cmped-10-2016-043">198</xref> while a small DBPC crossover trial using valproic acid did not show positive results.<xref ref-type="bibr" rid="b199-cmped-10-2016-043">199</xref> However, in this latter trial, valproic acid blood concentrations were supratherapeutic, potentially resulting in adverse cognitive effects.</p>
</sec>
<sec>
<title>Neurotransmitter treatments</title>
<p>Many of the medications used to manipulate dopamine and norepinephrine neurotransmission are used under the umbrella of attention-deficit hyperactivity disorder treatments. A recent systematic review of these treatments for ASD highlights the complicated nature of treatment due to the diverse nature of children with ASD and associated adverse effects.<xref ref-type="bibr" rid="b200-cmped-10-2016-043">200</xref> For example, despite studies showing positive effects of methylphenidate for hyperactivity, adverse effects are more prevalent in individuals with ASD resulting in a limitation of the dose that can be used.<xref ref-type="bibr" rid="b111-cmped-10-2016-043">111</xref>,<xref ref-type="bibr" rid="b200-cmped-10-2016-043">200</xref>,<xref ref-type="bibr" rid="b201-cmped-10-2016-043">201</xref> Atomoxetine has been found to be helpful with attention-deficit hyperactivity, but not social interaction, symptoms in two DBPC studies<xref ref-type="bibr" rid="b202-cmped-10-2016-043">202</xref>–<xref ref-type="bibr" rid="b205-cmped-10-2016-043">205</xref> and open-label extensions.<xref ref-type="bibr" rid="b206-cmped-10-2016-043">206</xref>,<xref ref-type="bibr" rid="b207-cmped-10-2016-043">207</xref> Atypical antipsychotics are very effective for behavioral symptoms associated with ASD, particularly irritability, stereotypy, and hyperactivity.<xref ref-type="bibr" rid="b208-cmped-10-2016-043">208</xref> However, they have significant detrimental effects on lipid, cholesterol and glucose metabolism, and body weight that develop quickly (within 12 weeks),<xref ref-type="bibr" rid="b209-cmped-10-2016-043">209</xref>,<xref ref-type="bibr" rid="b210-cmped-10-2016-043">210</xref> and they increase the risk of developing type 2 diabetes.<xref ref-type="bibr" rid="b211-cmped-10-2016-043">211</xref> Although the incidence is low, tardive dyskinesia, a potentially permanent movement disorder, is an additional risk.<xref ref-type="bibr" rid="b212-cmped-10-2016-043">212</xref> For several decades, the effectiveness of selective serotonin reuptake inhibitors has been studied, but a recent Cochrane review found no evidence for the efficacy of these medications in ASD.<xref ref-type="bibr" rid="b213-cmped-10-2016-043">213</xref></p>
<p>Given the evidence for an abnormal inhibitory–excitatory balance in the brain of individuals with ASD, several medications which target GABA and glutamate neurotransmission have been investigated, many based on the Fragile X mouse model of ASD.<xref ref-type="bibr" rid="b61-cmped-10-2016-043">61</xref>,<xref ref-type="bibr" rid="b214-cmped-10-2016-043">214</xref> Arbaclofen, a GABA agonist, demonstrated promising results in an open-label trial<xref ref-type="bibr" rid="b215-cmped-10-2016-043">215</xref> but failed to show efficacy in a DBPC trial.<xref ref-type="bibr" rid="b61-cmped-10-2016-043">61</xref> Recently, the diuretic bumetanide, a chloride-importer antagonist which modulates GABA neurotransmission, has demonstrated promising results in a DBPC study.<xref ref-type="bibr" rid="b216-cmped-10-2016-043">216</xref> In a DBPC study, <sc>l</sc>-carnosine, a modulator of GABA neurotransmission and an antioxidant, has been reported to improve core ASD symptoms and language.<xref ref-type="bibr" rid="b217-cmped-10-2016-043">217</xref> Acamprosate, a glutamate modulator, has demonstrated some positive results in small open-label<xref ref-type="bibr" rid="b218-cmped-10-2016-043">218</xref> and single-blind, placebo lead-in<xref ref-type="bibr" rid="b219-cmped-10-2016-043">219</xref> studies. Positive results in both large open-label and controlled studies have been reported for memantine, an <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist, with reported improvements in language, social function and behavior.<xref ref-type="bibr" rid="b58-cmped-10-2016-043">58</xref> Amantadine, also an <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist, has been shown in open-label and DBPC studies to improve speech, hyperactivity, and irritability in some children with ASD.<xref ref-type="bibr" rid="b220-cmped-10-2016-043">220</xref>–<xref ref-type="bibr" rid="b222-cmped-10-2016-043">222</xref>
<italic>N</italic>-Acetyl-<sc>l</sc>-cysteine, which provides the precursor to glutathione and reduces brain glutamate, has been shown to be effective in improving irritability and social functioning in ASD in DBPC studies.<xref ref-type="bibr" rid="b65-cmped-10-2016-043">65</xref>,<xref ref-type="bibr" rid="b223-cmped-10-2016-043">223</xref>,<xref ref-type="bibr" rid="b224-cmped-10-2016-043">224</xref> Thus, several agents have been investigated to target GABA and glutamate neurotransmission but, to date, only memantine, amantadine, and <italic>N</italic>-acetyl-<sc>l</sc>-cysteine have undergone multiple clinical trials. Other agents are promising but larger controlled clinical trials would be useful to confirm their efficacy.</p>
<p>In ASD, several medications that modulate acetylcholine have been investigated, including tacrine, donepezil, rivastigmine, and galantamine.<xref ref-type="bibr" rid="b58-cmped-10-2016-043">58</xref> Of these, only galantamine has demonstrated consistent positive results in controlled studies with reported improvements in both language and social functioning.</p>
<p>One area of growing interest is treatment with oxytocin nasal spray.<xref ref-type="bibr" rid="b66-cmped-10-2016-043">66</xref> Despite some studies showing promising results, other studies have failed to demonstrate an effect.<xref ref-type="bibr" rid="b225-cmped-10-2016-043">225</xref> In addition, the mechanism of action and the long-term effects of oxytocin are not known.<xref ref-type="bibr" rid="b66-cmped-10-2016-043">66</xref> Currently, a large multicenter trial is investigating the efficacy of oxytocin in ASD.</p>
<p>Lastly, it should be mentioned that neurotransmitter deficiencies that are secondary to metabolic abnormalities, such as tetrahydrobiopterin and/or folate deficiencies, should be corrected by addressing the metabolic disorder.</p>
</sec>
<sec>
<title>Sleep treatments</title>
<p>Sleep is extremely important in children with ASD, as studies have demonstrated that improving the quality of sleep often translates to improvements in daytime behavior.<xref ref-type="bibr" rid="b226-cmped-10-2016-043">226</xref> According to practice pathway guidelines, the treatment for sleep disorders in children with ASD starts with improving sleep hygiene and bedtime routine using behavioral parent training.<xref ref-type="bibr" rid="b227-cmped-10-2016-043">227</xref>,<xref ref-type="bibr" rid="b228-cmped-10-2016-043">228</xref> A number of pharmacological treatments are used to improve sleep in children with neurodevelopmental disorders but only melatonin has good empirical evidence for its effectiveness.<xref ref-type="bibr" rid="b229-cmped-10-2016-043">229</xref> Melatonin is perhaps the best studied nutritional supplement in the ASD population, having six DBPC studies confirming its efficacy for improving sleep onset and sleep duration,<xref ref-type="bibr" rid="b68-cmped-10-2016-043">68</xref>,<xref ref-type="bibr" rid="b69-cmped-10-2016-043">69</xref>,<xref ref-type="bibr" rid="b230-cmped-10-2016-043">230</xref> particularly when combined with cognitive-behavioral therapy.<xref ref-type="bibr" rid="b230-cmped-10-2016-043">230</xref> A recent open-label, dose escalation study demonstrated that 1–3 mg of melatonin was effective for most children within one week of treatment with the effect maintained over months without adverse effect.<xref ref-type="bibr" rid="b226-cmped-10-2016-043">226</xref></p>
<p>Not all sleep problems can be treated with behavioral training and melatonin. Other sleep disturbances such as nocturnal awakening do not appear to be treated effectively with melatonin and a comprehensive sleep history should be obtained from ASD children who have sleep disturbances in order to ensure that other sleep disorders such as sleep-disordered breathing and/or periodic limb movements during sleep are not present. In addition, since there is growing concern that GI problems also disrupt sleep, investigation and treatment for GI-related problems should also be considered.<xref ref-type="bibr" rid="b67-cmped-10-2016-043">67</xref> Since seizures can disrupt sleep in children with ASD, further evaluation with an overnight EEG may be warranted.<xref ref-type="bibr" rid="b231-cmped-10-2016-043">231</xref> Finally, clonidine has been shown to improve sleep in children with ASD as well as hyperactivity, social interaction, and ASD behaviors in open-label<xref ref-type="bibr" rid="b232-cmped-10-2016-043">232</xref>–<xref ref-type="bibr" rid="b234-cmped-10-2016-043">234</xref> and DBPC<xref ref-type="bibr" rid="b235-cmped-10-2016-043">235</xref> studies.</p>
</sec>
<sec>
<title>Metabolic disorders</title>
<sec>
<title>Folate metabolism</title>
<p>Reduced folates are common treatments of children with ASD. However, specific treatments for folate pathway polymorphisms have not been well studied. Research on treatments has concentrated on folate transport into the CNS. Individuals positive for FRα autoantibodies have been treated with 0.5–2 mg/kg/day of folinic acid, while individuals with MD may require up to 4 mg/kg/day of folinic acid. In addition, a milk-free diet has been shown to reduce serum FRα autoantibody titers in a controlled study.<xref ref-type="bibr" rid="b236-cmped-10-2016-043">236</xref> Multiple small and large case series have demonstrated that folinic acid treatment in ASD children who possess FRα autoantibodies can result in partial improvements in communication, social interaction, attention, and stereotypical behavior<xref ref-type="bibr" rid="b16-cmped-10-2016-043">16</xref>,<xref ref-type="bibr" rid="b93-cmped-10-2016-043">93</xref>,<xref ref-type="bibr" rid="b94-cmped-10-2016-043">94</xref>,<xref ref-type="bibr" rid="b236-cmped-10-2016-043">236</xref>,<xref ref-type="bibr" rid="b237-cmped-10-2016-043">237</xref> to complete recovery of ASD symptoms and other neurological problems such as seizures.<xref ref-type="bibr" rid="b94-cmped-10-2016-043">94</xref>,<xref ref-type="bibr" rid="b95-cmped-10-2016-043">95</xref></p>
</sec>
<sec>
<title>Cobalamin metabolism</title>
<p>A recent prospective, open-label study demonstrated that glutathione, but not methylation, metabolism could be normalized in children with ASD following a three-month supplementation with methylcobalamin injections and oral folinic acid.<xref ref-type="bibr" rid="b238-cmped-10-2016-043">238</xref> A follow-up study reported significant improvements in adaptive behaviors with this therapy, which correlated with improvements in glutathione metabolism.<xref ref-type="bibr" rid="b239-cmped-10-2016-043">239</xref> A small 12-week DBPC pilot study of injected methylcobalamin showed that clinical improvements occurred in participants who demonstrated improvements in glutathione metabolism.<xref ref-type="bibr" rid="b240-cmped-10-2016-043">240</xref> A recent eight-week DBPC study of 50 children with ASD found that methylcobalamin injections improved the Clinical Global Impression scale with improvements correlating with improvements in methylation metabolism.<xref ref-type="bibr" rid="b241-cmped-10-2016-043">241</xref></p>
</sec>
<sec>
<title>Tetrahydrobiopterin metabolism</title>
<p>Clinical trials conducted over the past 25 years have reported encouraging results using sapropterin, a synthetic form of BH<sub>4</sub>, to treat children with ASD.<xref ref-type="bibr" rid="b18-cmped-10-2016-043">18</xref> Three controlled<xref ref-type="bibr" rid="b242-cmped-10-2016-043">242</xref>–<xref ref-type="bibr" rid="b245-cmped-10-2016-043">245</xref> and several open-label trials have documented improvements in communication, cognitive ability, adaptability, social abilities, and verbal expression with sapropterin treatment in ASD, especially in children younger than five years of age and in those who are relatively higher functioning at the beginning of the trial.<xref ref-type="bibr" rid="b18-cmped-10-2016-043">18</xref></p>
<p>More recently, an open-label study demonstrated that sapropterin treatment improves redox metabolism and fundamentally alters BH<sub>4</sub> metabolism in children with ASD. Interestingly, serum biomarkers of nitric oxide metabolism were associated with a positive response to sapropterin treatment in children with ASD,<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref> thereby suggesting that the therapeutic effect of BH<sub>4</sub> supplementation may primarily involve nitric oxide metabolism. BH<sub>4</sub> supplementation could help stabilize nitric oxide synthase and act as an antioxidant and improve monoamine neurotransmitter production. Further DBPC studies incorporating biomarkers of metabolic pathways related to BH<sub>4</sub> metabolism will be needed to determine which children with ASD will most likely benefit from formulations of BH<sub>4</sub> supplementation such as sapropterin.</p>
</sec>
<sec>
<title>Carnitine metabolism</title>
<p>Several studies have reported improvements in core and associated ASD behaviors with <sc>l</sc>-carnitine treatment,<xref ref-type="bibr" rid="b20-cmped-10-2016-043">20</xref>,<xref ref-type="bibr" rid="b31-cmped-10-2016-043">31</xref>,<xref ref-type="bibr" rid="b245-cmped-10-2016-043">245</xref>–<xref ref-type="bibr" rid="b248-cmped-10-2016-043">248</xref> including two DBPC studies.<xref ref-type="bibr" rid="b249-cmped-10-2016-043">249</xref>,<xref ref-type="bibr" rid="b250-cmped-10-2016-043">250</xref> One DBPC study demonstrated that increases in serum carnitine levels correlated with improvements in cognitive and behavioral indexes in children with ASD.<xref ref-type="bibr" rid="b249-cmped-10-2016-043">249</xref> Carnitine has been suggested to help children with ASD and abnormal PPA metabolism,<xref ref-type="bibr" rid="b113-cmped-10-2016-043">113</xref> and a recent genetic disorder associated with ASD and abnormal carnitine metabolism could be responsive to supplemental carnitine.<xref ref-type="bibr" rid="b23-cmped-10-2016-043">23</xref></p>
</sec>
<sec>
<title>Redox metabolism</title>
<p>Treatments for oxidative stress have been shown to be beneficial for some children with ASD. Studies have demonstrated that glutathione metabolism can be improved in children with ASD with subcutaneously injected methylcobalamin,<xref ref-type="bibr" rid="b238-cmped-10-2016-043">238</xref>,<xref ref-type="bibr" rid="b239-cmped-10-2016-043">239</xref> a vitamin, and mineral supplement that includes antioxidants, coenzyme Q10 and B vitamin supplementation,<xref ref-type="bibr" rid="b251-cmped-10-2016-043">251</xref> and tetrahydrobiopterin.<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref>
<italic>N</italic>-Acetyl-<sc>l</sc>-cysteine, which can improve glutathione and reduce oxidative stress, has been shown to be effective in reducing irritability in several DBPC studies.<xref ref-type="bibr" rid="b65-cmped-10-2016-043">65</xref> These treatments have been reported to improve core ASD symptoms,<xref ref-type="bibr" rid="b223-cmped-10-2016-043">223</xref>,<xref ref-type="bibr" rid="b239-cmped-10-2016-043">239</xref> hyperactivity, tantruming and parental impression of general functioning,<xref ref-type="bibr" rid="b251-cmped-10-2016-043">251</xref> language,<xref ref-type="bibr" rid="b19-cmped-10-2016-043">19</xref> and irritability.<xref ref-type="bibr" rid="b223-cmped-10-2016-043">223</xref>,<xref ref-type="bibr" rid="b224-cmped-10-2016-043">224</xref> Although there are treatments that improve ASD symptoms which should also improve oxidative stress, such as the phytochemical sulforaphane,<xref ref-type="bibr" rid="b252-cmped-10-2016-043">252</xref> flavonoid luteolin,<xref ref-type="bibr" rid="b253-cmped-10-2016-043">253</xref> vitamin C<xref ref-type="bibr" rid="b254-cmped-10-2016-043">254</xref> and carnosine,<xref ref-type="bibr" rid="b217-cmped-10-2016-043">217</xref> the studies on these treatments did not include measures of oxidative stress to examine the biological mechanism of action. This is important as antioxidants can also treat mitochondrial dysfunction,<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> which is common in ASD. Overall, the data suggest that antioxidants may have a role in improving some ASD symptoms, but the exact treatment that is most effective and the targeted symptoms are not completely clear and require more study.</p>
</sec>
<sec>
<title>Mitochondrial metabolism</title>
<p>Children with ASD who have been diagnosed with classical MD have been given standard treatments for MD,<xref ref-type="bibr" rid="b255-cmped-10-2016-043">255</xref> including carnitine, coenzyme Q10, B vitamins, antioxidants, and vitamins C and E.<xref ref-type="bibr" rid="b14-cmped-10-2016-043">14</xref> However, mitochondrial treatments have not undergone critical efficacy or effectiveness studies in children with ASD and mitochondrial dysfunction. On the other hand, some treatments typically used for MD have been shown to improve core and associated symptoms of ASD in controlled studies. Such treatments include <sc>l</sc>-carnitine in two DBPC studies,<xref ref-type="bibr" rid="b249-cmped-10-2016-043">249</xref>,<xref ref-type="bibr" rid="b250-cmped-10-2016-043">250</xref> multivitamins containing B vitamins, antioxidants, vitamin E, and coenzyme Q10 in two DBPC studies,<xref ref-type="bibr" rid="b251-cmped-10-2016-043">251</xref>,<xref ref-type="bibr" rid="b256-cmped-10-2016-043">256</xref>
<italic>N</italic>-acetyl-<sc>l</sc>-cysteine in DBPC trials,<xref ref-type="bibr" rid="b65-cmped-10-2016-043">65</xref> and ubiquinol in an open-label trial.<xref ref-type="bibr" rid="b257-cmped-10-2016-043">257</xref> Many of these treatments may also address other metabolic problems associated with ASD, so in many studies, it is not clear that such treatments specifically address mitochondrial disorders or other metabolic abnormalities, or both. Thus, although it is important to consider these treatments in children with ASD, further studies are needed to determine the biological targets of these treatments and the best biomarkers to identify children with ASD who might benefit from these treatments.</p>
</sec>
<sec>
<title>Cholesterol metabolism</title>
<p>In children with Smith-Lemli-Opitz syndrome, supplementation with cholesterol has been shown to reduce autistic behaviors as well as irritability, temper tantrums, hyperactivity, aggressive behaviors, self-injurious behaviors, and trichotillomania.<xref ref-type="bibr" rid="b258-cmped-10-2016-043">258</xref> Studies using cholesterol as a treatment in children with ASD who also have low cholesterol are needed to confirm these findings.</p>
</sec>
</sec>
<sec>
<title>Immune disorders</title>
<p>IVIG has been shown in several studies to improve symptoms of autism, including improvements in aberrant behavior<xref ref-type="bibr" rid="b259-cmped-10-2016-043">259</xref> and speech and social interaction<xref ref-type="bibr" rid="b150-cmped-10-2016-043">150</xref> and autistic behavior.<xref ref-type="bibr" rid="b260-cmped-10-2016-043">260</xref> One study reported significant improvements in children with ASD receiving IVIG in Aberrant Behavior Checklist (ABC) irritability, hyperactivity, and inappropriate speech and eye contact compared to those receiving placebo injections.<xref ref-type="bibr" rid="b261-cmped-10-2016-043">261</xref> Another study demonstrated regression with the discontinuation of IVIG treatment.<xref ref-type="bibr" rid="b259-cmped-10-2016-043">259</xref> In contrast, other smaller case series did not find improvements in children with ASD.<xref ref-type="bibr" rid="b262-cmped-10-2016-043">262</xref>,<xref ref-type="bibr" rid="b263-cmped-10-2016-043">263</xref> IVIG is a potential treatment for children with ASD who show autoantibodies including those associated with PANDAS, as IVIG has been used successfully to treat PANDAS type symptoms in placebo controlled studies,<xref ref-type="bibr" rid="b264-cmped-10-2016-043">264</xref> case reports,<xref ref-type="bibr" rid="b265-cmped-10-2016-043">265</xref> and case series.<xref ref-type="bibr" rid="b266-cmped-10-2016-043">266</xref> Oral immunoglobulin has also been used for the treatment of GI symptoms. One small open-label study suggested a 50% response rate,<xref ref-type="bibr" rid="b267-cmped-10-2016-043">267</xref> but a larger DBPC study did not find any significant effects.<xref ref-type="bibr" rid="b268-cmped-10-2016-043">268</xref></p>
<p>Some modulators of inflammation have also been studied. Celecoxib, a nonsteroidal anti-inflammatory drug, has been shown to improve irritability, social withdrawal, and stereotypic behavior, as measured by the ABC, in a DBPC trial when added to risperidone.<xref ref-type="bibr" rid="b269-cmped-10-2016-043">269</xref> Pentoxifylline, a drug that is believed to decrease TNF-α, a cytokine that has been shown to be elevated in some children with ASD in the blood and CNS,<xref ref-type="bibr" rid="b270-cmped-10-2016-043">270</xref> has been shown to improve all subscales of the ABC when added to risperidone in a DBPC trial.<xref ref-type="bibr" rid="b271-cmped-10-2016-043">271</xref> In prospective<xref ref-type="bibr" rid="b272-cmped-10-2016-043">272</xref> and retrospective<xref ref-type="bibr" rid="b273-cmped-10-2016-043">273</xref> open-label trials, steroids used in combination with valproic acid in patients with epileptic aphasia demonstrated a marked improvement in language in a majority of the patients. In a prospective open-label pilot study, low partial pressure hyperbaric oxygen was found to improve C-reactive protein, suggesting it provided improvement in inflammatory processes.<xref ref-type="bibr" rid="b274-cmped-10-2016-043">274</xref></p>
</sec>
<sec>
<title>GI treatments</title>
<p>Although many standard GI treatments are applied to GI symptoms in children with ASD, many children are refractory to such treatments, leading to the use of many novel GI treatments aimed at eliminating specific foods that the child may be sensitive to, or treatments that address microbiome imbalances.<xref ref-type="bibr" rid="b168-cmped-10-2016-043">168</xref>,<xref ref-type="bibr" rid="b169-cmped-10-2016-043">169</xref>,<xref ref-type="bibr" rid="b275-cmped-10-2016-043">275</xref> A consensus statement developed by a multidisciplinary panel suggested that children with ASD deserve the same standard of care GI workup as non-ASD children.<xref ref-type="bibr" rid="b169-cmped-10-2016-043">169</xref> This group also pointed out that children with ASD might present with behavioral symptoms rather than more typical GI symptoms as manifestations of GI disease.<xref ref-type="bibr" rid="b168-cmped-10-2016-043">168</xref> For example, children with ASD and esophagitis sometimes present with aggressive or self-injurious behaviors.<xref ref-type="bibr" rid="b286-cmped-10-2016-043">286</xref> This group also developed guidelines based on expert opinion for the workup and treatment of children with ASD.<xref ref-type="bibr" rid="b168-cmped-10-2016-043">168</xref> Overall, they suggested that treatments should be targeted at symptomology and findings from a clinical evaluation. The report concentrated on diarrhea, constipation, and gastroesophageal reflux disease, all very common problems in children with ASD. For the most part, the group recommended standard of care GI therapy based on the differential diagnosis.</p>
<p>Many novel therapies targeting GI processes are commonly provided to children with ASD. Similar to standard treatments for GI symptoms, these treatments have a limited evidence base, although some have been evaluated in clinical trials.</p>
<p>It is common for children with ASD to be treated with various dietary interventions. The more common dietary treatments include the GFCF diet, specific carbohydrate diet, or the MAD. Several studies have examined the effectiveness of the GFCF diet. Although small studies have been inconsistent,<xref ref-type="bibr" rid="b277-cmped-10-2016-043">277</xref>,<xref ref-type="bibr" rid="b278-cmped-10-2016-043">278</xref> one larger single-blind study has been more promising.<xref ref-type="bibr" rid="b279-cmped-10-2016-043">279</xref> One study suggested that the GFCF diet was most effective in children with GI symptoms, food allergies, or sensitivities and/or those whose caretakers could implement it consistently.<xref ref-type="bibr" rid="b280-cmped-10-2016-043">280</xref> Several groups believe that the MAD or ketogenic diet may be helpful in children with ASD,<xref ref-type="bibr" rid="b281-cmped-10-2016-043">281</xref> especially those with epilesy.<xref ref-type="bibr" rid="b50-cmped-10-2016-043">50</xref> Studying the efficacy of dietary interventions in children with ASD can be particularly difficult as children with ASD sometimes self-restrict what they eat, and dietary changes need to be coordinated with other caretakers such as school officials. In addition, behavioral and biological changes resulting from dietary changes may require several months or more to observe.</p>
<p>Since some children with ASD have been shown to have deficits in enzymes responsible for carbohydrate digestion,<xref ref-type="bibr" rid="b171-cmped-10-2016-043">171</xref> several studies have examined the effect of digestive enzyme supplementation. While an open-label study that provided a comprehensive enzyme that helped with both carbohydrate and protein digestion at every meal reported promising results,<xref ref-type="bibr" rid="b283-cmped-10-2016-043">283</xref> a DBPC crossover study, which used a digestive enzyme, which only helped with protein digestion given only one meal per day did not show any effect, except for a small statistically significant improvement in food variety scores.<xref ref-type="bibr" rid="b283-cmped-10-2016-043">283</xref> However, a more recent three-month DBPC of 101 children with ASD reported significant improvements in autistic behaviors, emotional response, and GI symptoms with digestive enzyme treatment compared to placebo.<xref ref-type="bibr" rid="b284-cmped-10-2016-043">284</xref></p>
<p>Still other treatments have focused on altering imbalances in the microbiome.<xref ref-type="bibr" rid="b275-cmped-10-2016-043">275</xref> Temporary improvements in ASD symptoms were found in a partially blinded clinical trial of oral vancomycin, an antibiotic that targets <italic>Clostridium</italic> genus and is not absorbed systematically, conducted on children with ASD who had GI symptoms and irritability.<xref ref-type="bibr" rid="b186-cmped-10-2016-043">186</xref> One open-label study using probiotics in children with ASD reported improvements in concentration and following directions,<xref ref-type="bibr" rid="b285-cmped-10-2016-043">285</xref> and a DBPC crossover study documented improvements in stool consistency and ASD behaviors as well as a reduction in <italic>Clostridium</italic> species using a probiotic containing lactobacillus compared to placebo.<xref ref-type="bibr" rid="b286-cmped-10-2016-043">286</xref> A summary of the findings of a working group that discussed this topic was recently published. This working group included clinicians, research scientists, and parents of children with ASD and was an extension of the First International Symposium on the Microbiome in Health and Disease with a Special Focus on Autism (<ext-link ext-link-type="uri" xlink:href="http://www.microbiome-autism.com">www.microbiome-autism.com</ext-link>).<xref ref-type="bibr" rid="b275-cmped-10-2016-043">275</xref></p>
</sec>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>This manuscript reviews pathophysiological abnormalities that have been found to be consistently associated with ASD in multiple studies. Overall, we found there is evidence that ASD is associated with seizure and epilepsy, neurotransmitter disorders, sleep abnormalities, metabolic imbalances including abnormalities in folate, cobalamin, tetrahydrobiopterin, carnitine, redox and mitochondrial metabolism, and immune and GI disorders. Although evidence for an association between these pathophysiological abnormalities and ASD exist, further research is needed to better define the exact relationship between these identified pathophysiological abnormalities and ASD. For example, the relationship between the etiology of ASD and these pathophysiological abnormalities is not clear. It is possible that some of these abnormalities could cause brain dysfunction that could result in core or associated ASD symptoms, while it is also possible that processes that result in brain dysfunction could also cause these associated pathophysiological abnormalities. Since, at this point, these pathophysio logical abnormalities are identified and studied after the diagnosis of ASD, the temporal relationship between these abnormalities and the processes that cause ASD is uncertain.</p>
<p>Evidence for the significance of these pathophysiological abnormalities can be derived from determining whether or not treatments that target specific pathophysiological abnormalities are effective at improving core and/or associated ASD symptoms. Studies examining treatments vary in quality with many preliminary studies. Targeted treatments specific for ASD-associated pathophysiological abnormalities that have been studied in high-quality clinical trials including treatments for neurotransmitter abnormities, particularly imbalances in glutamate and acetylcholine, sleep onset disorder with behavioral therapy and melatonin, and metabolic abnormalities in folate, cobalamin, tetrahydrobiopterin, carnitine, and redox abnormalities. Clinical studies have also examined specific treatments for epilepsy and seizures, mitochondrial and immune disorders, and GI abnormalities, particularly imbalances in the enteric microbiome, but the studies are overall preliminary and require further clinical trials.</p>
<p>Clearly, there are some promising areas of ASD research that could lead to novel treatments, but more research is needed to better study these treatments. One particular challenge when studying children with ASD is the fact that there is significant heterogeneity in this population and that certain pathophysiological abnormalities probably only affect specific subgroups of children with ASD. Thus, first defining these subgroups before applying targeted treatments may be the best approach, but reliable biomarkers have not been developed for many of these pathophysiological abnormalities.</p>
<p>Until further information is available on many of these treatments, it is reasonable to empirically treat children with ASD who are identified with specifically pathophysiological abnormalities if careful follow-up is maintained, and the medical professional is knowledgable regarding the treatment, particularly for treatments that have highly favorable adverse effect profiles and for patients that are unresponsive to standard behavioral therapy. As more information becomes available, treatment guidelines can be developed. Overall, the development of treatments that target specific pathophysiological disorders has the potential to provide significant improvement in the lives of children with ASD and their families.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported in part by the Arkansas Biosciences Institute, Little Rock, AR USA.</p>
</ack>
<fn-group>
<fn id="fn1-cmped-10-2016-043">
<p><bold>ACADEMIC EDITOR:</bold> Praveen Kumar, Editor in Chief</p>
</fn>
<fn id="fn2-cmped-10-2016-043">
<p><bold>PEER REVIEW:</bold> Three peer reviewers contributed to the peer review report. Reviewers’ reports totaled 350 words, excluding any confidential comments to the academic editor.</p>
</fn>
<fn id="fn3-cmped-10-2016-043">
<p><bold>FUNDING:</bold> Dr Frye is funded by the Arkansas Biosciences Institute, Little Rock, AR USA. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.</p>
</fn>
<fn id="fn4-cmped-10-2016-043">
<p><bold>COMPETING INTERESTS:</bold> Authors disclose no potential conflicts of interest.</p>
</fn>
<fn id="fn5-cmped-10-2016-043">
<p>Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE). Provenance: the authors were invited to submit this paper.</p>
</fn>
<fn id="fn6-cmped-10-2016-043">
<p>
<bold>Author Contributions</bold>
</p>
<p>Conceived and designed the experiments: REF, DAR. Analyzed the data: REF, DAR. Wrote the first draft of the manuscript: REF. Contributed to the writing of the manuscript: REF, DAR. Agree with manuscript results and conclusions: REF, DAR. Jointly developed the structure and arguments for the paper: REF, DAR. Made critical revisions and approved final version: REF, DAR. Both authors reviewed and approved of the final manuscript.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="b1-cmped-10-2016-043">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures</article-title>
<source/>Mol Psychiatry
          <year>2012</year>
<volume>17</volume>
<issue>4</issue>
<fpage>389</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">22143005</pub-id>
</element-citation>
</ref>
<ref id="b2-cmped-10-2016-043">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zablotsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Maenner</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Schieve</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 National Health Interview Survey</article-title>
<source/>Natl Health Stat Report
          <year>2015</year>
<volume>87</volume>
<fpage>1</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">26632847</pub-id>
</element-citation>
</ref>
<ref id="b3-cmped-10-2016-043">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reichow</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD)</article-title>
<source/>Cochrane Database Syst Rev
          <year>2012</year>
<volume>10</volume>
<fpage>CD009260</fpage>
<pub-id pub-id-type="pmid">23076956</pub-id>
</element-citation>
</ref>
<ref id="b4-cmped-10-2016-043">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Mendelsohn</surname>
<given-names>NJ</given-names>
</name>
<collab>Professional Practice and Guidelines Committee</collab>
</person-group>
<article-title>Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions</article-title>
<source/>Genet Med
          <year>2013</year>
<volume>15</volume>
<issue>5</issue>
<fpage>399</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">23519317</pub-id>
</element-citation>
</ref>
<ref id="b5-cmped-10-2016-043">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neale</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Kou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patterns and rates of exonic de novo mutations in autism spectrum disorders</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<issue>7397</issue>
<fpage>242</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">22495311</pub-id>
</element-citation>
</ref>
<ref id="b6-cmped-10-2016-043">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations revealed by whole-exome sequencing are strongly associated with autism</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<issue>7397</issue>
<fpage>237</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">22495306</pub-id>
</element-citation>
</ref>
<ref id="b7-cmped-10-2016-043">
<label>7</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>SG</given-names>
</name>
</person-group>
<source/>Autism: From Behavior to Biology
          <publisher-loc>New York, NY</publisher-loc>
<publisher-name>Huffington Post</publisher-name>
<year>2015</year>
</element-citation>
</ref>
<ref id="b8-cmped-10-2016-043">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Beyond genetics in autism</article-title>
<source/>Autism Res Rev Int
          <year>2015</year>
<volume>29</volume>
<issue>3</issue>
<fpage>6</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="b9-cmped-10-2016-043">
<label>9</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<source/>The Science Behind the Healthy Child Guide
          <publisher-loc>Dallas, TX</publisher-loc>
<publisher-name>The Neurological Health Foundation</publisher-name>
<year>2016</year>
</element-citation>
</ref>
<ref id="b10-cmped-10-2016-043">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallmayer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic heritability and shared environmental factors among twin pairs with autism</article-title>
<source/>Arch Gen Psychiatry
          <year>2011</year>
<volume>68</volume>
<issue>11</issue>
<fpage>1095</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">21727249</pub-id>
</element-citation>
</ref>
<ref id="b11-cmped-10-2016-043">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lichtenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kuja-Halkola</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Reichenberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The familial risk of autism</article-title>
<source/>JAMA
          <year>2014</year>
<volume>311</volume>
<issue>17</issue>
<fpage>1770</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24794370</pub-id>
</element-citation>
</ref>
<ref id="b12-cmped-10-2016-043">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Genuis</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Environmental toxicants and autism spectrum disorders: a systematic review</article-title>
<source/>Transl Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e360</fpage>
<pub-id pub-id-type="pmid">24518398</pub-id>
</element-citation>
</ref>
<ref id="b13-cmped-10-2016-043">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Metabolic pathology of autism in relation to redox metabolism</article-title>
<source/>Biomark Med
          <year>2014</year>
<volume>8</volume>
<issue>3</issue>
<fpage>321</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">24712422</pub-id>
</element-citation>
</ref>
<ref id="b14-cmped-10-2016-043">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis</article-title>
<source/>Mol Psychiatry
          <year>2012</year>
<volume>17</volume>
<issue>3</issue>
<fpage>290</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="pmid">21263444</pub-id>
</element-citation>
</ref>
<ref id="b15-cmped-10-2016-043">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders</article-title>
<source/>Pediatr Res
          <year>2011</year>
<volume>69</volume>
<issue>5 pt 2</issue>
<fpage>41R</fpage>
<lpage>7R</lpage>
</element-citation>
</ref>
<ref id="b16-cmped-10-2016-043">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Cerebral folate receptor autoantibodies in autism spectrum disorder</article-title>
<source/>Mol Psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>3</issue>
<fpage>369</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">22230883</pub-id>
</element-citation>
</ref>
<ref id="b17-cmped-10-2016-043">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Central tetrahydrobiopterin concentration in neurodevelopmental disorders</article-title>
<source/>Front Neurosci
          <year>2010</year>
<volume>4</volume>
<fpage>52</fpage>
<pub-id pub-id-type="pmid">20661295</pub-id>
</element-citation>
</ref>
<ref id="b18-cmped-10-2016-043">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Tetrahydrobiopterin as a novel therapeutic intervention for autism</article-title>
<source/>Neurotherapeutics
          <year>2010</year>
<volume>7</volume>
<issue>3</issue>
<fpage>241</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">20643376</pub-id>
</element-citation>
</ref>
<ref id="b19-cmped-10-2016-043">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>DeLatorre</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>HB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e237</fpage>
<pub-id pub-id-type="pmid">23462988</pub-id>
</element-citation>
</ref>
<ref id="b20-cmped-10-2016-043">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gargus</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Familial autism with primary carnitine deficiency, sudden death, hypotonia and hypochromic anemia</article-title>
<source/>Am J Hum Genet
          <year>1997</year>
<volume>61</volume>
<fpage>A98</fpage>
</element-citation>
</ref>
<ref id="b21-cmped-10-2016-043">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Macfabe</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e220</fpage>
<pub-id pub-id-type="pmid">23340503</pub-id>
</element-citation>
</ref>
<ref id="b22-cmped-10-2016-043">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filipek</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Juranek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gargus</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Relative carnitine deficiency in autism</article-title>
<source/>J Autism Dev Disord
          <year>2004</year>
<volume>34</volume>
<issue>6</issue>
<fpage>615</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">15679182</pub-id>
</element-citation>
</ref>
<ref id="b23-cmped-10-2016-043">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celestino-Soper</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Violante</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>EL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<issue>21</issue>
<fpage>7974</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">22566635</pub-id>
</element-citation>
</ref>
<ref id="b24-cmped-10-2016-043">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosser</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hirt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Janc</surname>
<given-names>OA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>48</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">22750529</pub-id>
</element-citation>
</ref>
<ref id="b25-cmped-10-2016-043">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Slobedman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>NH</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain</article-title>
<source/>BMC Neurosci
          <year>2010</year>
<volume>11</volume>
<fpage>53</fpage>
<pub-id pub-id-type="pmid">20420693</pub-id>
</element-citation>
</ref>
<ref id="b26-cmped-10-2016-043">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Condie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wainwright</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Acquired microcephaly, regression of milestones, mitochondrial dysfunction, and episodic rigidity in a 46,XY male with a de novo MECP2 gene mutation</article-title>
<source/>J Child Neurol
          <year>2010</year>
<volume>25</volume>
<issue>5</issue>
<fpage>633</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">20142466</pub-id>
</element-citation>
</ref>
<ref id="b27-cmped-10-2016-043">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ross-Inta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>8</issue>
<fpage>e42504</fpage>
<pub-id pub-id-type="pmid">22900024</pub-id>
</element-citation>
</ref>
<ref id="b28-cmped-10-2016-043">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Mitochondrial disease in 22q13 duplication syndrome</article-title>
<source/>J Child Neurol
          <year>2012</year>
<volume>27</volume>
<issue>7</issue>
<fpage>942</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22378673</pub-id>
</element-citation>
</ref>
<ref id="b29-cmped-10-2016-043">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction may explain symptom variation in Phelan-McDermid syndrome</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>19544</fpage>
<pub-id pub-id-type="pmid">26822410</pub-id>
</element-citation>
</ref>
<ref id="b30-cmped-10-2016-043">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>15q11.2-13 duplication, mitochondrial dysfunction, and developmental disorders</article-title>
<source/>J Child Neurol
          <year>2009</year>
<volume>24</volume>
<issue>10</issue>
<fpage>1316</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">19535813</pub-id>
</element-citation>
</ref>
<ref id="b31-cmped-10-2016-043">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filipek</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Juranek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in autistic patients with 15q inverted duplication</article-title>
<source/>Ann Neurol
          <year>2003</year>
<volume>53</volume>
<issue>6</issue>
<fpage>801</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">12783428</pub-id>
</element-citation>
</ref>
<ref id="b32-cmped-10-2016-043">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>PE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3 A deficient mouse model for Angelman syndrome</article-title>
<source/>Neurosci Lett
          <year>2011</year>
<volume>487</volume>
<issue>2</issue>
<fpage>129</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">19563863</pub-id>
</element-citation>
</ref>
<ref id="b33-cmped-10-2016-043">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuelke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krude</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Finckh</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Septo-optic dysplasia associated with a new mitochondrial cytochrome b mutation</article-title>
<source/>Ann Neurol
          <year>2002</year>
<volume>51</volume>
<issue>3</issue>
<fpage>388</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">11891837</pub-id>
</element-citation>
</ref>
<ref id="b34-cmped-10-2016-043">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Oxidative stress and mitochondrial dysfunction in down syndrome</article-title>
<source/>Adv Exp Med Biol
          <year>2012</year>
<volume>724</volume>
<fpage>291</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22411251</pub-id>
</element-citation>
</ref>
<ref id="b35-cmped-10-2016-043">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallardo</surname>
<given-names>FV</given-names>
</name>
<name>
<surname>Lloret</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lebel</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in some oxidative stress-related genetic diseases: ataxia-telangiectasia, down syndrome, Fanconi anaemia and Werner syndrome</article-title>
<source/>Biogerontology
          <year>2010</year>
<volume>11</volume>
<issue>4</issue>
<fpage>401</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">20237955</pub-id>
</element-citation>
</ref>
<ref id="b36-cmped-10-2016-043">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuchman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rapin</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Epilepsy in autism</article-title>
<source/>Lancet Neurol
          <year>2002</year>
<volume>1</volume>
<issue>6</issue>
<fpage>352</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">12849396</pub-id>
</element-citation>
</ref>
<ref id="b37-cmped-10-2016-043">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deykin</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>MacMahon</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The incidence of seizures among children with autistic symptoms</article-title>
<source/>Am J Psychiatry
          <year>1979</year>
<volume>136</volume>
<issue>10</issue>
<fpage>1310</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">484727</pub-id>
</element-citation>
</ref>
<ref id="b38-cmped-10-2016-043">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volkmar</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Seizure disorders in autism</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1990</year>
<volume>29</volume>
<issue>1</issue>
<fpage>127</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">2295565</pub-id>
</element-citation>
</ref>
<ref id="b39-cmped-10-2016-043">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danielsson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Billstedt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Epilepsy in young adults with autism: a prospective population-based follow-up study of 120 individuals diagnosed in childhood</article-title>
<source/>Epilepsia
          <year>2005</year>
<volume>46</volume>
<issue>6</issue>
<fpage>918</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">15946331</pub-id>
</element-citation>
</ref>
<ref id="b40-cmped-10-2016-043">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Autism and epilepsy: a retrospective follow-up study</article-title>
<source/>Brain Dev
          <year>2007</year>
<volume>29</volume>
<issue>8</issue>
<fpage>486</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">17321709</pub-id>
</element-citation>
</ref>
<ref id="b41-cmped-10-2016-043">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackmon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bluvstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>MacAllister</surname>
<given-names>WS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment resistant epilepsy in autism spectrum disorder: increased risk for females</article-title>
<source/>Autism Res
          <year>2016</year>
<volume>9</volume>
<issue>2</issue>
<fpage>311</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">26112160</pub-id>
</element-citation>
</ref>
<ref id="b42-cmped-10-2016-043">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sansa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Medically refractory epilepsy in autism</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<issue>6</issue>
<fpage>1071</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">21671922</pub-id>
</element-citation>
</ref>
<ref id="b43-cmped-10-2016-043">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gourfinkel-An</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bouzamondo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis</article-title>
<source/>Biol Psychiatry
          <year>2008</year>
<volume>64</volume>
<issue>7</issue>
<fpage>577</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">18565495</pub-id>
</element-citation>
</ref>
<ref id="b44-cmped-10-2016-043">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Achkar CM</surname>
<given-names>Spence SJ</given-names>
</name>
</person-group>
<article-title>Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>47</volume>
<fpage>183</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">25599987</pub-id>
</element-citation>
</ref>
<ref id="b45-cmped-10-2016-043">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pickett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tuchman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lajonchere</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Mortality in individuals with autism, with and without epilepsy</article-title>
<source/>J Child Neurol
          <year>2011</year>
<volume>26</volume>
<issue>8</issue>
<fpage>932</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">21471551</pub-id>
</element-citation>
</ref>
<ref id="b46-cmped-10-2016-043">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shavelle</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Pickett</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Causes of death in autism</article-title>
<source/>J Autism Dev Disord
          <year>2001</year>
<volume>31</volume>
<issue>6</issue>
<fpage>569</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">11814268</pub-id>
</element-citation>
</ref>
<ref id="b47-cmped-10-2016-043">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jabbari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nurnberg</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A genomic view on epilepsy and autism candidate genes</article-title>
<source/>Genomics
          <year>2016</year>
<comment>In press</comment>
</element-citation>
</ref>
<ref id="b48-cmped-10-2016-043">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Paciorkowski</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder and epilepsy: disorders with a shared biology</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>47</volume>
<fpage>191</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">25900226</pub-id>
</element-citation>
</ref>
<ref id="b49-cmped-10-2016-043">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>47</volume>
<fpage>147</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">25440829</pub-id>
</element-citation>
</ref>
<ref id="b50-cmped-10-2016-043">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel</article-title>
<source/>Front Public Health
          <year>2013</year>
<volume>1</volume>
<fpage>31</fpage>
<pub-id pub-id-type="pmid">24350200</pub-id>
</element-citation>
</ref>
<ref id="b51-cmped-10-2016-043">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krasne</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coughlan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kominsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005</article-title>
<source/>Epilepsy Behav
          <year>2006</year>
<volume>8</volume>
<issue>1</issue>
<fpage>267</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">16403678</pub-id>
</element-citation>
</ref>
<ref id="b52-cmped-10-2016-043">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munoz-Yunta</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Palau-Baduell</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Magnetoencephalographic pattern of epileptiform activity in children with early-onset autism spectrum disorders</article-title>
<source/>Clin Neurophysiol
          <year>2008</year>
<volume>119</volume>
<issue>3</issue>
<fpage>626</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">18164240</pub-id>
</element-citation>
</ref>
<ref id="b53-cmped-10-2016-043">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parmeggiani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barcia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Posar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raimondi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Santucci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scaduto</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Epilepsy and EEG paroxysmal abnormalities in autism spectrum disorders</article-title>
<source/>Brain Dev
          <year>2010</year>
<volume>32</volume>
<issue>9</issue>
<fpage>783</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">20691552</pub-id>
</element-citation>
</ref>
<ref id="b54-cmped-10-2016-043">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oslejskova</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dusek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Makovska</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pejcochova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Autrata</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Slapak</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Complicated relationship between autism with regression and epilepsy</article-title>
<source/>Neuro Endocrinol Lett
          <year>2008</year>
<volume>29</volume>
<issue>4</issue>
<fpage>558</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">18766162</pub-id>
</element-citation>
</ref>
<ref id="b55-cmped-10-2016-043">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Strickland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Papanicolaou</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Electroencephalogram discharges in atypical cognitive development</article-title>
<source/>J Child Neurol
          <year>2010</year>
<volume>25</volume>
<issue>5</issue>
<fpage>556</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">20299700</pub-id>
</element-citation>
</ref>
<ref id="b56-cmped-10-2016-043">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Prevalence, significance and clinical characteristics of seizures, epilepsy and subclinical electrical activity in autism</article-title>
<source/>N Am J Med Sci
          <year>2015</year>
<volume>8</volume>
<issue>3</issue>
<fpage>113</fpage>
<lpage>22</lpage>
</element-citation>
</ref>
<ref id="b57-cmped-10-2016-043">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartley-McAndrew</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weinstock</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder: correlation between aberrant behaviors, EEG abnormalities and seizures</article-title>
<source/>Neurol Int
          <year>2010</year>
<volume>2</volume>
<issue>1</issue>
<fpage>e10</fpage>
<pub-id pub-id-type="pmid">21577334</pub-id>
</element-citation>
</ref>
<ref id="b58-cmped-10-2016-043">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>The use of medications approved for Alzheimer’s disease in autism spectrum disorder: a systematic review</article-title>
<source/>Front Pediatr
          <year>2014</year>
<volume>2</volume>
<fpage>87</fpage>
<pub-id pub-id-type="pmid">25202686</pub-id>
</element-citation>
</ref>
<ref id="b59-cmped-10-2016-043">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberman</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders</article-title>
<source/>Expert Opin Investig Drugs
          <year>2012</year>
<volume>21</volume>
<issue>12</issue>
<fpage>1819</fpage>
<lpage>25</lpage>
</element-citation>
</ref>
<ref id="b60-cmped-10-2016-043">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maloney</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Rieger</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dougherty</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Identifying essential cell types and circuits in autism spectrum disorders</article-title>
<source/>Int Rev Neurobiol
          <year>2013</year>
<volume>113</volume>
<fpage>61</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">24290383</pub-id>
</element-citation>
</ref>
<ref id="b61-cmped-10-2016-043">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder</article-title>
<source/>Drug Healthc Patient Saf
          <year>2014</year>
<volume>6</volume>
<fpage>69</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">24872724</pub-id>
</element-citation>
</ref>
<ref id="b62-cmped-10-2016-043">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Treatments for biomedical abnormalities associated with autism spectrum disorder</article-title>
<source/>Front Pediatr
          <year>2014</year>
<volume>2</volume>
<fpage>66</fpage>
<pub-id pub-id-type="pmid">25019065</pub-id>
</element-citation>
</ref>
<ref id="b63-cmped-10-2016-043">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pavliv</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain</article-title>
<source/>Transl Psychiatry
          <year>2012</year>
<volume>2</volume>
<fpage>e134</fpage>
<pub-id pub-id-type="pmid">22781167</pub-id>
</element-citation>
</ref>
<ref id="b64-cmped-10-2016-043">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism</article-title>
<source/>Front Physiol
          <year>2014</year>
<volume>5</volume>
<fpage>150</fpage>
<pub-id pub-id-type="pmid">24795645</pub-id>
</element-citation>
</ref>
<ref id="b65-cmped-10-2016-043">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deepmala</surname>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review</article-title>
<source/>Neurosci Biobehav Rev
          <year>2015</year>
<volume>55</volume>
<fpage>294</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">25957927</pub-id>
</element-citation>
</ref>
<ref id="b66-cmped-10-2016-043">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefevre</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sirigu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The two fold role of oxytocin in social developmental disorders: a cause and a remedy?</article-title>
<source/>Neurosci Biobehav Rev
          <year>2016</year>
<volume>63</volume>
<fpage>168</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">26828138</pub-id>
</element-citation>
</ref>
<ref id="b67-cmped-10-2016-043">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klukowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wasilewska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lebensztejn</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Sleep and gastrointestinal disturbances in autism spectrum disorder in children</article-title>
<source/>Dev Period Med
          <year>2015</year>
<volume>19</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">26384115</pub-id>
</element-citation>
</ref>
<ref id="b68-cmped-10-2016-043">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Melatonin in autism spectrum disorders</article-title>
<source/>Curr Clin Pharmacol
          <year>2014</year>
<volume>9</volume>
<issue>4</issue>
<fpage>326</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">24050742</pub-id>
</element-citation>
</ref>
<ref id="b69-cmped-10-2016-043">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Melatonin in autism spectrum disorders: a systematic review and meta-analysis</article-title>
<source/>Dev Med Child Neurol
          <year>2011</year>
<volume>53</volume>
<issue>9</issue>
<fpage>783</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">21518346</pub-id>
</element-citation>
</ref>
<ref id="b70-cmped-10-2016-043">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadeau</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frequency and clinical correlates of sleep-related problems among anxious youth with autism spectrum disorders</article-title>
<source/>Child Psychiatry Hum Dev
          <year>2015</year>
<volume>46</volume>
<issue>4</issue>
<fpage>558</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">25239284</pub-id>
</element-citation>
</ref>
<ref id="b71-cmped-10-2016-043">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Zuckerman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>AD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aggressive behavior problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample</article-title>
<source/>Res Autism Spectr Disord
          <year>2014</year>
<volume>8</volume>
<issue>9</issue>
<fpage>1121</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">25221619</pub-id>
</element-citation>
</ref>
<ref id="b72-cmped-10-2016-043">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tilford</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Payakachat</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kuhlthau</surname>
<given-names>KA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment for sleep problems in children with autism and caregiver spillover effects</article-title>
<source/>J Autism Dev Disord
          <year>2015</year>
<volume>45</volume>
<issue>11</issue>
<fpage>3613</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">26126749</pub-id>
</element-citation>
</ref>
<ref id="b73-cmped-10-2016-043">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tordjman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Bellissant</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder</article-title>
<source/>Psychoneuroendocrinology
          <year>2012</year>
<volume>37</volume>
<issue>12</issue>
<fpage>1990</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">22613035</pub-id>
</element-citation>
</ref>
<ref id="b74-cmped-10-2016-043">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tordjman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Pichard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Charbuy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Touitou</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder</article-title>
<source/>Biol Psychiatry
          <year>2005</year>
<volume>57</volume>
<issue>2</issue>
<fpage>134</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">15652871</pub-id>
</element-citation>
</ref>
<ref id="b75-cmped-10-2016-043">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leu</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Beyderman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Botzolakis</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Surdyka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Relation of melatonin to sleep architecture in children with autism</article-title>
<source/>J Autism Dev Disord
          <year>2011</year>
<volume>41</volume>
<issue>4</issue>
<fpage>427</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">20683768</pub-id>
</element-citation>
</ref>
<ref id="b76-cmped-10-2016-043">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Callebert</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders</article-title>
<source/>Transl Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e479</fpage>
<pub-id pub-id-type="pmid">25386956</pub-id>
</element-citation>
</ref>
<ref id="b77-cmped-10-2016-043">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goubran Botros</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chaste</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal melatonin synthesis in autism spectrum disorders</article-title>
<source/>Mol Psychiatry
          <year>2008</year>
<volume>13</volume>
<issue>1</issue>
<fpage>90</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">17505466</pub-id>
</element-citation>
</ref>
<ref id="b78-cmped-10-2016-043">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Mitochondrial and metabolic abnormalities in neurodevelopmental disorders</article-title>
<source/>J Pediatr Biochem
          <year>2012</year>
<volume>4</volume>
<issue>2</issue>
<fpage>177</fpage>
<lpage>80</lpage>
</element-citation>
</ref>
<ref id="b79-cmped-10-2016-043">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obeid</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McCaddon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases</article-title>
<source/>Clin Chem Lab Med
          <year>2007</year>
<volume>45</volume>
<issue>12</issue>
<fpage>1590</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">18067446</pub-id>
</element-citation>
</ref>
<ref id="b80-cmped-10-2016-043">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frustaci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cesario</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress-related biomarkers in autism: systematic review and meta-analyses</article-title>
<source/>Free Radic Biol Med
          <year>2012</year>
<volume>52</volume>
<issue>10</issue>
<fpage>2128</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">22542447</pub-id>
</element-citation>
</ref>
<ref id="b81-cmped-10-2016-043">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galanko</surname>
<given-names>J</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Association of MTHFR gene variants with autism</article-title>
<source/>J Am Phys Surg
          <year>2004</year>
<volume>9</volume>
<issue>4</issue>
<fpage>106</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="b82-cmped-10-2016-043">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammad</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Chintakindi</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Naik</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Akella</surname>
<given-names>RR</given-names>
</name>
</person-group>
<article-title>Aberrations in folate metabolic pathway and altered susceptibility to autism</article-title>
<source/>Psychiatr Genet
          <year>2009</year>
<volume>19</volume>
<issue>4</issue>
<fpage>171</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19440165</pub-id>
</element-citation>
</ref>
<ref id="b83-cmped-10-2016-043">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Methylenetetrahydrofolate reductase polymorphisms C677T and risk of autism in the Chinese Han population</article-title>
<source/>Genet Test Mol Biomarkers
          <year>2012</year>
<volume>16</volume>
<issue>8</issue>
<fpage>968</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">22775456</pub-id>
</element-citation>
</ref>
<ref id="b84-cmped-10-2016-043">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tancredi</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ozonoff</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study</article-title>
<source/>Am J Clin Nutr
          <year>2012</year>
<volume>96</volume>
<issue>1</issue>
<fpage>80</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22648721</pub-id>
</element-citation>
</ref>
<ref id="b85-cmped-10-2016-043">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Solehdin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>IL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Population- and family-based studies associate the MTHFR gene with idiopathic autism in simplex families</article-title>
<source/>J Autism Dev Disord
          <year>2011</year>
<volume>41</volume>
<issue>7</issue>
<fpage>938</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">21069446</pub-id>
</element-citation>
</ref>
<ref id="b86-cmped-10-2016-043">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goin-Kochel</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Shinawi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>The MTHFR 677C–&gt;T polymorphism and behaviors in children with autism: exploratory genotype-phenotype correlations</article-title>
<source/>Autism Res
          <year>2009</year>
<volume>2</volume>
<issue>2</issue>
<fpage>98</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">19455642</pub-id>
</element-citation>
</ref>
<ref id="b87-cmped-10-2016-043">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasca</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Dronca</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kaucsar</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders</article-title>
<source/>J Cell Mol Med
          <year>2009</year>
<volume>13</volume>
<issue>10</issue>
<fpage>4229</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">19267885</pub-id>
</element-citation>
</ref>
<ref id="b88-cmped-10-2016-043">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jernigan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2006</year>
<volume>141B</volume>
<issue>8</issue>
<fpage>947</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">16917939</pub-id>
</element-citation>
</ref>
<ref id="b89-cmped-10-2016-043">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Association between MTHFR gene polymorphisms and the risk of autism spectrum disorders: a meta-analysis</article-title>
<source/>Autism Res
          <year>2013</year>
<volume>6</volume>
<issue>5</issue>
<fpage>384</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">23653228</pub-id>
</element-citation>
</ref>
<ref id="b90-cmped-10-2016-043">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lucock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fardell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Preliminary evidence for involvement of the folate gene polymorphism 19 bp deletion-DHFR in occurrence of autism</article-title>
<source/>Neurosci Lett
          <year>2007</year>
<volume>422</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">17597297</pub-id>
</element-citation>
</ref>
<ref id="b91-cmped-10-2016-043">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Naviaux</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Autistic disorder with complex IV overactivity: a new mitochondrial syndrome</article-title>
<source/>J Pediatr Neurol
          <year>2011</year>
<volume>9</volume>
<issue>4</issue>
<fpage>427</fpage>
<lpage>34</lpage>
</element-citation>
</ref>
<ref id="b92-cmped-10-2016-043">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Role of folate receptor autoantibodies in infantile autism</article-title>
<source/>Mol Psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>3</issue>
<fpage>270</fpage>
<lpage>1</lpage>
<pub-id pub-id-type="pmid">22488256</pub-id>
</element-citation>
</ref>
<ref id="b93-cmped-10-2016-043">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Del Gaudio</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency</article-title>
<source/>J Autism Dev Disord
          <year>2008</year>
<volume>38</volume>
<issue>6</issue>
<fpage>1170</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">18027081</pub-id>
</element-citation>
</ref>
<ref id="b94-cmped-10-2016-043">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Rothenberg</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autoantibodies to folate receptors in the cerebral folate deficiency syndrome</article-title>
<source/>N Engl J Med
          <year>2005</year>
<volume>352</volume>
<issue>19</issue>
<fpage>1985</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">15888699</pub-id>
</element-citation>
</ref>
<ref id="b95-cmped-10-2016-043">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Blau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Nassogne</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits</article-title>
<source/>Neuropediatrics
          <year>2007</year>
<volume>38</volume>
<issue>6</issue>
<fpage>276</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">18461502</pub-id>
</element-citation>
</ref>
<ref id="b96-cmped-10-2016-043">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>The metabolic basis for developmental disorders due to defective folate transport</article-title>
<source/>Biochimie
          <year>2016</year>
<comment>In press</comment>
</element-citation>
</ref>
<ref id="b97-cmped-10-2016-043">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hodgson</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>MS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased brain levels of vitamin B12 in aging, autism and schizophrenia</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>1</issue>
<fpage>e0146797</fpage>
<pub-id pub-id-type="pmid">26799654</pub-id>
</element-citation>
</ref>
<ref id="b98-cmped-10-2016-043">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark-Taylor</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Clark-Taylor</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase</article-title>
<source/>Med Hypotheses
          <year>2004</year>
<volume>62</volume>
<issue>6</issue>
<fpage>970</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15142659</pub-id>
</element-citation>
</ref>
<ref id="b99-cmped-10-2016-043">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macfabe</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders</article-title>
<source/>Microb Ecol Health Dis
          <year>2012</year>
<volume>23</volume>
<fpage>19260</fpage>
</element-citation>
</ref>
<ref id="b100-cmped-10-2016-043">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmieri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in autism spectrum disorders: cause or effect?</article-title>
<source/>Biochim Biophys Acta
          <year>2010</year>
<volume>1797</volume>
<issue>6–7</issue>
<fpage>1130</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">20441769</pub-id>
</element-citation>
</ref>
<ref id="b101-cmped-10-2016-043">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trusty</surname>
<given-names>TA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism</article-title>
<source/>Autism Res Treat
          <year>2012</year>
<volume>2012</volume>
<fpage>986519</fpage>
<pub-id pub-id-type="pmid">22928106</pub-id>
</element-citation>
</ref>
<ref id="b102-cmped-10-2016-043">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>3</issue>
<fpage>367</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">21519954</pub-id>
</element-citation>
</ref>
<ref id="b103-cmped-10-2016-043">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism</article-title>
<source/>Am J Clin Nutr
          <year>2004</year>
<volume>80</volume>
<issue>6</issue>
<fpage>1611</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15585776</pub-id>
</element-citation>
</ref>
<ref id="b104-cmped-10-2016-043">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>1</issue>
<fpage>e85436</fpage>
<pub-id pub-id-type="pmid">24416410</pub-id>
</element-citation>
</ref>
<ref id="b105-cmped-10-2016-043">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism</article-title>
<source/>FASEB J
          <year>2009</year>
<volume>23</volume>
<issue>8</issue>
<fpage>2374</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">19307255</pub-id>
</element-citation>
</ref>
<ref id="b106-cmped-10-2016-043">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Delatorre</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Redox metabolism abnormalities in autistic children associated with mitochondrial disease</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e273</fpage>
<pub-id pub-id-type="pmid">23778583</pub-id>
</element-citation>
</ref>
<ref id="b107-cmped-10-2016-043">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines</article-title>
<source/>Transl Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e377</fpage>
<pub-id pub-id-type="pmid">24690598</pub-id>
</element-citation>
</ref>
<ref id="b108-cmped-10-2016-043">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wynne</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines</article-title>
<source/>J Toxicol
          <year>2015</year>
<volume>2015</volume>
<fpage>573701</fpage>
<pub-id pub-id-type="pmid">25688267</pub-id>
</element-citation>
</ref>
<ref id="b109-cmped-10-2016-043">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Metabolic disorders and abnormalities associated with autism spectrum disorder</article-title>
<source/>J Pediatr Biochem
          <year>2012</year>
<volume>2</volume>
<fpage>181</fpage>
<lpage>91</lpage>
</element-citation>
</ref>
<ref id="b110-cmped-10-2016-043">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fillano</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Goldenthal</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Marin-Garcia</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome</article-title>
<source/>J Child Neurol
          <year>2002</year>
<volume>17</volume>
<issue>6</issue>
<fpage>435</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">12174964</pub-id>
</element-citation>
</ref>
<ref id="b111-cmped-10-2016-043">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Diogo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grazina</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in autism spectrum disorders: a population-based study</article-title>
<source/>Dev Med Child Neurol
          <year>2005</year>
<volume>47</volume>
<issue>3</issue>
<fpage>185</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15739723</pub-id>
</element-citation>
</ref>
<ref id="b112-cmped-10-2016-043">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Biomarker of abnormal energy metabolism in children with autism spectrum disorder</article-title>
<source/>N Am J Med Sci
          <year>2012</year>
<volume>5</volume>
<fpage>141</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="b113-cmped-10-2016-043">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome</article-title>
<source/>Microb Ecol Health Dis
          <year>2015</year>
<volume>26</volume>
<fpage>27458</fpage>
<pub-id pub-id-type="pmid">25956238</pub-id>
</element-citation>
</ref>
<ref id="b114-cmped-10-2016-043">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giulivi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Omanska-Klusek</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in autism</article-title>
<source/>JAMA
          <year>2010</year>
<volume>304</volume>
<issue>21</issue>
<fpage>2389</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">21119085</pub-id>
</element-citation>
</ref>
<ref id="b115-cmped-10-2016-043">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Deficits in bioenergetics and impaired immune response in granulocytes from children with autism</article-title>
<source/>Pediatrics
          <year>2014</year>
<volume>133</volume>
<issue>5</issue>
<fpage>e1405</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">24753527</pub-id>
</element-citation>
</ref>
<ref id="b116-cmped-10-2016-043">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graf</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Marin-Garcia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>HG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism associated with the mitochondrial DNA G8363 A transfer RNA<sup>Lys</sup> mutation</article-title>
<source/>J Child Neurol
          <year>2000</year>
<volume>15</volume>
<fpage>357</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">10868777</pub-id>
</element-citation>
</ref>
<ref id="b117-cmped-10-2016-043">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Novel cytochrome B gene mutations causing mitochondrial disease in autism</article-title>
<source/>J Pediatr Neurol
          <year>2012</year>
<volume>10</volume>
<fpage>35</fpage>
<lpage>40</lpage>
</element-citation>
</ref>
<ref id="b118-cmped-10-2016-043">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmieri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Papaleo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Porcelli</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1</article-title>
<source/>Mol Psychiatry
          <year>2010</year>
<volume>15</volume>
<issue>1</issue>
<fpage>38</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">18607376</pub-id>
</element-citation>
</ref>
<ref id="b119-cmped-10-2016-043">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tierney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bukelis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormalities of cholesterol metabolism in autism spectrum disorders</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2006</year>
<volume>141</volume>
<issue>6</issue>
<fpage>666</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16874769</pub-id>
</element-citation>
</ref>
<ref id="b120-cmped-10-2016-043">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moses</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weizman</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Metabolic profiles in adults with autism spectrum disorder and intellectual disabilities</article-title>
<source/>Eur Psychiatry
          <year>2014</year>
<volume>29</volume>
<issue>7</issue>
<fpage>397</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">23849396</pub-id>
</element-citation>
</ref>
<ref id="b121-cmped-10-2016-043">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Neggers</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Alterations in lipid profile of autistic boys: a case control study</article-title>
<source/>Nutr Res
          <year>2010</year>
<volume>30</volume>
<issue>4</issue>
<fpage>255</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">20534328</pub-id>
</element-citation>
</ref>
<ref id="b122-cmped-10-2016-043">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikora</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Pettit-Kekel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Penfield</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Merkens</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome</article-title>
<source/>Am J Med Genet A
          <year>2006</year>
<volume>140</volume>
<issue>14</issue>
<fpage>1511</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16761297</pub-id>
</element-citation>
</ref>
<ref id="b123-cmped-10-2016-043">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukelis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Tierney</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Smith-Lemli-Opitz syndrome and autism spectrum disorder</article-title>
<source/>Am J Psychiatry
          <year>2007</year>
<volume>164</volume>
<issue>11</issue>
<fpage>1655</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">17974928</pub-id>
</element-citation>
</ref>
<ref id="b124-cmped-10-2016-043">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foley</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Kavaliers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ossenkopp</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Sexually dimorphic effects of prenatal exposure to lipopolysaccharide, and prenatal and postnatal exposure to propionic acid, on acoustic startle response and prepulse inhibition in adolescent rats: relevance to autism spectrum disorders</article-title>
<source/>Behav Brain Res
          <year>2015</year>
<volume>278</volume>
<fpage>244</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">25300465</pub-id>
</element-citation>
</ref>
<ref id="b125-cmped-10-2016-043">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foley</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Ossenkopp</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Kavaliers</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Macfabe</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Pre- and neonatal exposure to lipopolysaccharide or the enteric metabolite, propionic acid, alters development and behavior in adolescent rats in a sexually dimorphic manner</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>1</issue>
<fpage>e87072</fpage>
<pub-id pub-id-type="pmid">24466331</pub-id>
</element-citation>
</ref>
<ref id="b126-cmped-10-2016-043">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derecki</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Cronk</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wild-type microglia arrest pathology in a mouse model of Rett syndrome</article-title>
<source/>Nature
          <year>2012</year>
<volume>484</volume>
<issue>7392</issue>
<fpage>105</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22425995</pub-id>
</element-citation>
</ref>
<ref id="b127-cmped-10-2016-043">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Kitchener</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Serum anti-nuclear antibodies as markers of autoimmunity in Egyptian autistic children</article-title>
<source/>Pediatr Neurol
          <year>2009</year>
<volume>40</volume>
<issue>2</issue>
<fpage>107</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">19135624</pub-id>
</element-citation>
</ref>
<ref id="b128-cmped-10-2016-043">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>AL-Ayadhi</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Serum antinucleosome-specific antibody as a marker of autoimmunity in children with autism</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<issue>1</issue>
<fpage>69</fpage>
<pub-id pub-id-type="pmid">24708718</pub-id>
</element-citation>
</ref>
<ref id="b129-cmped-10-2016-043">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khakzad</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Javanbakht</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shayegan</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The complementary role of high sensitivity C-reactive protein in the diagnosis and severity assessment of autism</article-title>
<source/>Res Autism Spectr Disord
          <year>2012</year>
<volume>6</volume>
<issue>3</issue>
<fpage>1032</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="b130-cmped-10-2016-043">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gesundheit</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rosenzweig</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Naor</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunological and autoimmune considerations of autism spectrum disorders</article-title>
<source/>J Autoimmun
          <year>2013</year>
<volume>44</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">23867105</pub-id>
</element-citation>
</ref>
<ref id="b131-cmped-10-2016-043">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Angelidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>KD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children</article-title>
<source/>J Neuroinflammation
          <year>2010</year>
<volume>7</volume>
<issue>1</issue>
<fpage>80</fpage>
<pub-id pub-id-type="pmid">21083929</pub-id>
</element-citation>
</ref>
<ref id="b132-cmped-10-2016-043">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Streif</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy</article-title>
<source/>Biol Psychiatry
          <year>2006</year>
<volume>59</volume>
<issue>4</issue>
<fpage>354</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">16181614</pub-id>
</element-citation>
</ref>
<ref id="b133-cmped-10-2016-043">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Pestronk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deuel</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders</article-title>
<source/>J Pediatr
          <year>1999</year>
<volume>134</volume>
<issue>5</issue>
<fpage>607</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">10228297</pub-id>
</element-citation>
</ref>
<ref id="b134-cmped-10-2016-043">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bashir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Endothelial antibody levels in the sera of children with autism spectrum disorders</article-title>
<source/>J Chin Med Assoc
          <year>2015</year>
<volume>78</volume>
<issue>7</issue>
<fpage>414</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">26087852</pub-id>
</element-citation>
</ref>
<ref id="b135-cmped-10-2016-043">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Careaga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hertz-Piccotto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Increased anti-phospholipid antibodies in autism spectrum disorders</article-title>
<source/>Mediators Inflamm
          <year>2013</year>
<volume>2013</volume>
<fpage>935608</fpage>
<pub-id pub-id-type="pmid">24174712</pub-id>
</element-citation>
</ref>
<ref id="b136-cmped-10-2016-043">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goines</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haapanen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autoantibodies to cerebellum in children with autism associate with behavior</article-title>
<source/>Brain Behav Immun
          <year>2011</year>
<volume>25</volume>
<issue>3</issue>
<fpage>514</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">21134442</pub-id>
</element-citation>
</ref>
<ref id="b137-cmped-10-2016-043">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>39</fpage>
<pub-id pub-id-type="pmid">21513576</pub-id>
</element-citation>
</ref>
<ref id="b138-cmped-10-2016-043">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafa</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>The relationship between the increased frequency of serum antineuronal antibodies and the severity of autism in children</article-title>
<source/>Eur J Paediatr Neurol
          <year>2012</year>
<volume>16</volume>
<issue>5</issue>
<fpage>464</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">22226851</pub-id>
</element-citation>
</ref>
<ref id="b139-cmped-10-2016-043">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greengard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Valtorta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Czernik</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Benfenati</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Synaptic vesicle phosphoproteins and regulation of synaptic function</article-title>
<source/>Science
          <year>1993</year>
<volume>259</volume>
<issue>5096</issue>
<fpage>780</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">8430330</pub-id>
</element-citation>
</ref>
<ref id="b140-cmped-10-2016-043">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffith</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The multifunctional Ca2+/calmodulin-dependent protein kinase mediates Ca2+-dependent phosphorylation of tyrosine hydroxylase</article-title>
<source/>J Biol Chem
          <year>1988</year>
<volume>263</volume>
<issue>19</issue>
<fpage>9542</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">2897967</pub-id>
</element-citation>
</ref>
<ref id="b141-cmped-10-2016-043">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrabarty</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bhattacharyya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Christopher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Glutamatergic dysfunction in OCD</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<issue>9</issue>
<fpage>1735</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">15841109</pub-id>
</element-citation>
</ref>
<ref id="b142-cmped-10-2016-043">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirvan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Heuser</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea</article-title>
<source/>Nat Med
          <year>2003</year>
<volume>9</volume>
<issue>7</issue>
<fpage>914</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">12819778</pub-id>
</element-citation>
</ref>
<ref id="b143-cmped-10-2016-043">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirvan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Snider</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Antibody-mediated neuronal cell signaling in behavior and movement disorders</article-title>
<source/>J Neuroimmunol
          <year>2006</year>
<volume>179</volume>
<issue>1–2</issue>
<fpage>173</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">16875742</pub-id>
</element-citation>
</ref>
<ref id="b144-cmped-10-2016-043">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Duncanson</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism-specific maternal autoantibodies recognize critical proteins in developing brain</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e277</fpage>
<pub-id pub-id-type="pmid">23838888</pub-id>
</element-citation>
</ref>
<ref id="b145-cmped-10-2016-043">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cabanlit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism</article-title>
<source/>Brain Behav Immun
          <year>2008</year>
<volume>22</volume>
<issue>6</issue>
<fpage>806</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">18262386</pub-id>
</element-citation>
</ref>
<ref id="b146-cmped-10-2016-043">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauman</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Iosif</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey</article-title>
<source/>Transl Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e278</fpage>
<pub-id pub-id-type="pmid">23838889</pub-id>
</element-citation>
</ref>
<ref id="b147-cmped-10-2016-043">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piras</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Haapanen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Napolioni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with autism spectrum disorder</article-title>
<source/>Brain Behav Immun
          <year>2014</year>
<volume>38</volume>
<fpage>91</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">24389156</pub-id>
</element-citation>
</ref>
<ref id="b148-cmped-10-2016-043">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordahl</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Braunschweig</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iosif</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder</article-title>
<source/>Brain Behav Immun
          <year>2013</year>
<volume>30</volume>
<fpage>61</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">23395715</pub-id>
</element-citation>
</ref>
<ref id="b149-cmped-10-2016-043">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pellicer</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Torrente</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walker-Smith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wakefield</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology</article-title>
<source/>J Clin Immunol
          <year>2003</year>
<volume>23</volume>
<issue>6</issue>
<fpage>504</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">15031638</pub-id>
</element-citation>
</ref>
<ref id="b150-cmped-10-2016-043">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heads</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics</article-title>
<source/>J Autism Dev Disord
          <year>1996</year>
<volume>26</volume>
<issue>4</issue>
<fpage>439</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">8863094</pub-id>
</element-citation>
</ref>
<ref id="b151-cmped-10-2016-043">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heuer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schauer</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms</article-title>
<source/>Autism Res
          <year>2008</year>
<volume>1</volume>
<issue>5</issue>
<fpage>275</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">19343198</pub-id>
</element-citation>
</ref>
<ref id="b152-cmped-10-2016-043">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhry</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shahzad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Serum Immunoglobulins and CRP levels in autistic children</article-title>
<source/>Biomedica
          <year>2015</year>
<volume>31</volume>
<issue>3</issue>
<fpage>215</fpage>
</element-citation>
</ref>
<ref id="b153-cmped-10-2016-043">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croonenberghs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wauters</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Devreese</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism</article-title>
<source/>Psychol Med
          <year>2002</year>
<volume>32</volume>
<issue>8</issue>
<fpage>1457</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">12455944</pub-id>
</element-citation>
</ref>
<ref id="b154-cmped-10-2016-043">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trajkovski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ajdinski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spiroski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Plasma concentration of immunoglobulin classes and subclasses in children with autism in the Republic of Macedonia: retrospective study</article-title>
<source/>Croat Med J
          <year>2004</year>
<volume>45</volume>
<issue>6</issue>
<fpage>746</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15578810</pub-id>
</element-citation>
</ref>
<ref id="b155-cmped-10-2016-043">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiroski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Trajkovski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Trajkov</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Family analysis of immunoglobulin classes and subclasses in children with autistic disorder</article-title>
<source/>Bosn J Basic Med Sci
          <year>2009</year>
<volume>9</volume>
<issue>4</issue>
<fpage>283</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">20001993</pub-id>
</element-citation>
</ref>
<ref id="b156-cmped-10-2016-043">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heuer</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ashwood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van de Water</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction</article-title>
<source/>J Neuroimmunol
          <year>2012</year>
<volume>251</volume>
<issue>1–2</issue>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">22854260</pub-id>
</element-citation>
</ref>
<ref id="b157-cmped-10-2016-043">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enstrom</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krakowiak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Onore</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased IgG4 levels in children with autism disorder</article-title>
<source/>Brain Behav Immun
          <year>2009</year>
<volume>23</volume>
<issue>3</issue>
<fpage>389</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">19136055</pub-id>
</element-citation>
</ref>
<ref id="b158-cmped-10-2016-043">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grether</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Yolken</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Neonatally measured immunoglobulins and risk of autism</article-title>
<source/>Autism Res
          <year>2010</year>
<volume>3</volume>
<issue>6</issue>
<fpage>323</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">21182209</pub-id>
</element-citation>
</ref>
<ref id="b159-cmped-10-2016-043">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nascimbene</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>
<source/>Ann Neurol
          <year>2005</year>
<volume>57</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">15546155</pub-id>
</element-citation>
</ref>
<ref id="b160-cmped-10-2016-043">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<volume>68</volume>
<issue>4</issue>
<fpage>368</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">20674603</pub-id>
</element-citation>
</ref>
<ref id="b161-cmped-10-2016-043">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetreault</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Hakeem</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglia in the cerebral cortex in autism</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>12</issue>
<fpage>2569</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">22466688</pub-id>
</element-citation>
</ref>
<ref id="b162-cmped-10-2016-043">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugihara</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ouchi</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microglial activation in young adults with autism spectrum disorder</article-title>
<source/>JAMA Psychiatry
          <year>2013</year>
<volume>70</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">23404112</pub-id>
</element-citation>
</ref>
<ref id="b163-cmped-10-2016-043">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Abramson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Semendeferi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Everall</surname>
<given-names>IP</given-names>
</name>
</person-group>
<article-title>Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1456</volume>
<fpage>72</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">22516109</pub-id>
</element-citation>
</ref>
<ref id="b164-cmped-10-2016-043">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quintana</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Glozier</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hickie</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Guastella</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Cytokine abberations in autism spectrum disorder: a systematic review and meta-analysis</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>4</issue>
<fpage>440</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">24934179</pub-id>
</element-citation>
</ref>
<ref id="b165-cmped-10-2016-043">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated immune response in the brain of autistic patients</article-title>
<source/>J Neuroimmunol
          <year>2009</year>
<volume>207</volume>
<issue>1–2</issue>
<fpage>111</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19157572</pub-id>
</element-citation>
</ref>
<ref id="b166-cmped-10-2016-043">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sheikh</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation</article-title>
<source/>J Neuroinflammation
          <year>2011</year>
<volume>8</volume>
<fpage>52</fpage>
<pub-id pub-id-type="pmid">21595886</pub-id>
</element-citation>
</ref>
<ref id="b167-cmped-10-2016-043">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Toruner</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes</article-title>
<source/>J Neuroimmunol
          <year>2011</year>
<volume>238</volume>
<issue>1–2</issue>
<fpage>73</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">21803429</pub-id>
</element-citation>
</ref>
<ref id="b168-cmped-10-2016-043">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>GJ</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Furuta</surname>
<given-names>GT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs</article-title>
<source/>Pediatrics
          <year>2010</year>
<volume>125</volume>
<issue>suppl 1</issue>
<fpage>S19</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">20048084</pub-id>
</element-citation>
</ref>
<ref id="b169-cmped-10-2016-043">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>GJ</given-names>
<suffix>III</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report</article-title>
<source/>Pediatrics
          <year>2010</year>
<volume>125</volume>
<issue>suppl 1</issue>
<fpage>S1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">20048083</pub-id>
</element-citation>
</ref>
<ref id="b170-cmped-10-2016-043">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bresnahan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>AF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of maternal report of infant and toddler gastrointestinal symptoms with autism: evidence from a prospective birth cohort</article-title>
<source/>JAMA Psychiatry
          <year>2015</year>
<volume>72</volume>
<issue>5</issue>
<fpage>466</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">25806498</pub-id>
</element-citation>
</ref>
<ref id="b171-cmped-10-2016-043">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>9</issue>
<fpage>e24585</fpage>
<pub-id pub-id-type="pmid">21949732</pub-id>
</element-citation>
</ref>
<ref id="b172-cmped-10-2016-043">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claus</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Ellero</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Colonization-induced host-gut microbial metabolic interaction</article-title>
<source/>MBio
          <year>2011</year>
<volume>2</volume>
<issue>2</issue>
<fpage>e271</fpage>
<lpage>e210</lpage>
</element-citation>
</ref>
<ref id="b173-cmped-10-2016-043">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kinross</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Host-gut microbiota metabolic interactions</article-title>
<source/>Science
          <year>2012</year>
<volume>336</volume>
<issue>6086</issue>
<fpage>1262</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">22674330</pub-id>
</element-citation>
</ref>
<ref id="b174-cmped-10-2016-043">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenderov</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Midtvedt</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Epigenomic programing: a future way to health?</article-title>
<source/>Microb Ecol Health Dis
          <year>2014</year>
<volume>25</volume>
<fpage>24145</fpage>
</element-citation>
</ref>
<ref id="b175-cmped-10-2016-043">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alenghat</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Epigenomics and the microbiota</article-title>
<source/>Toxicol Pathol
          <year>2015</year>
<volume>43</volume>
<issue>1</issue>
<fpage>101</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">25330924</pub-id>
</element-citation>
</ref>
<ref id="b176-cmped-10-2016-043">
<label>176</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diaz Heijtz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anuar</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Normal gut microbiota modulates brain development and behavior</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<issue>7</issue>
<fpage>3047</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">21282636</pub-id>
</element-citation>
</ref>
<ref id="b177-cmped-10-2016-043">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hsien</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders</article-title>
<source/>Cell
          <year>2013</year>
<volume>155</volume>
<issue>7</issue>
<fpage>1451</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">24315484</pub-id>
</element-citation>
</ref>
<ref id="b178-cmped-10-2016-043">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Christophersen</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Sorich</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Angley</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Conlon</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Increased abundance of <italic>Sutterella spp</italic>. and <italic>Ruminococcus torques</italic> in feces of children with autism spectrum disorder</article-title>
<source/>Mol Autism
          <year>2013</year>
<volume>4</volume>
<issue>1</issue>
<fpage>42</fpage>
<pub-id pub-id-type="pmid">24188502</pub-id>
</element-citation>
</ref>
<ref id="b179-cmped-10-2016-043">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Conlon</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Christophersen</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Sorich</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Angley</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders</article-title>
<source/>Biomark Med
          <year>2014</year>
<volume>8</volume>
<issue>3</issue>
<fpage>331</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">24712423</pub-id>
</element-citation>
</ref>
<ref id="b180-cmped-10-2016-043">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Ilhan</surname>
<given-names>ZE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>7</issue>
<fpage>e68322</fpage>
<pub-id pub-id-type="pmid">23844187</pub-id>
</element-citation>
</ref>
<ref id="b181-cmped-10-2016-043">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krajmalnik-Brown</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lozupone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease</article-title>
<source/>Microb Ecol Health Dis
          <year>2015</year>
<volume>26</volume>
<fpage>26914</fpage>
<pub-id pub-id-type="pmid">25769266</pub-id>
</element-citation>
</ref>
<ref id="b182-cmped-10-2016-043">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilbo</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Nevison</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>A model for the induction of autism in the ecosystem of the human body: the anatomy of a modern pandemic?</article-title>
<source/>Microb Ecol Health Dis
          <year>2015</year>
<volume>26</volume>
<fpage>26253</fpage>
<pub-id pub-id-type="pmid">25634608</pub-id>
</element-citation>
</ref>
<ref id="b183-cmped-10-2016-043">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Angelis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Piccolo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vannini</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>10</issue>
<fpage>e76993</fpage>
<pub-id pub-id-type="pmid">24130822</pub-id>
</element-citation>
</ref>
<ref id="b184-cmped-10-2016-043">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buie</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Potential etiologic factors of microbiome disruption in autism</article-title>
<source/>Clin Ther
          <year>2015</year>
<volume>37</volume>
<issue>5</issue>
<fpage>976</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">26046240</pub-id>
</element-citation>
</ref>
<ref id="b185-cmped-10-2016-043">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finegold</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Desulfovibrio species are potentially important in regressive autism</article-title>
<source/>Med Hypotheses
          <year>2011</year>
<volume>77</volume>
<issue>2</issue>
<fpage>270</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">21592674</pub-id>
</element-citation>
</ref>
<ref id="b186-cmped-10-2016-043">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandler</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Finegold</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bolte</surname>
<given-names>ER</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Short-term benefit from oral vancomycin treatment of regressive-onset autism</article-title>
<source/>J Child Neurol
          <year>2000</year>
<volume>15</volume>
<issue>7</issue>
<fpage>429</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">10921511</pub-id>
</element-citation>
</ref>
<ref id="b187-cmped-10-2016-043">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macfabe</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Autism: metabolism, mitochondria, and the microbiome</article-title>
<source/>Glob Adv Health Med
          <year>2013</year>
<volume>2</volume>
<issue>6</issue>
<fpage>52</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">24416709</pub-id>
</element-citation>
</ref>
<ref id="b188-cmped-10-2016-043">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ossenkopp</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic treatment with the enteric bacterial fermentation product, propionic acid, produces both conditioned taste avoidance and conditioned place avoidance in rats</article-title>
<source/>Behav Brain Res
          <year>2012</year>
<volume>227</volume>
<issue>1</issue>
<fpage>134</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">22085877</pub-id>
</element-citation>
</ref>
<ref id="b189-cmped-10-2016-043">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Cain</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Rodriguez-Capote</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders</article-title>
<source/>Behav Brain Res
          <year>2007</year>
<volume>176</volume>
<issue>1</issue>
<fpage>149</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">16950524</pub-id>
</element-citation>
</ref>
<ref id="b190-cmped-10-2016-043">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kesli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gokcen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bulug</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Terzi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Investigation of the relation between anaerobic bacteria genus clostridium and late-onset autism etiology in children</article-title>
<source/>J Immunoassay Immunochem
          <year>2014</year>
<volume>35</volume>
<issue>1</issue>
<fpage>101</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">24063620</pub-id>
</element-citation>
</ref>
<ref id="b191-cmped-10-2016-043">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Sreenivasula</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey</article-title>
<source/>BMC Pediatr
          <year>2011</year>
<volume>11</volume>
<fpage>37</fpage>
<pub-id pub-id-type="pmid">21592359</pub-id>
</element-citation>
</ref>
<ref id="b192-cmped-10-2016-043">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billiau</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Witters</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ceulemans</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kasran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lagae</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<issue>9</issue>
<fpage>1739</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">17521345</pub-id>
</element-citation>
</ref>
<ref id="b193-cmped-10-2016-043">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kurdi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>El-Khoury</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rahi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raad</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature</article-title>
<source/>Epilepsy Behav
          <year>2010</year>
<volume>17</volume>
<issue>1</issue>
<fpage>90</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">20004620</pub-id>
</element-citation>
</ref>
<ref id="b194-cmped-10-2016-043">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Engelen</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Renier</surname>
<given-names>WO</given-names>
</name>
<name>
<surname>Weemaes</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gabreels</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Meinardi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Immunoglobulin treatment in epilepsy, a review of the literature</article-title>
<source/>Epilepsy Res
          <year>1994</year>
<volume>19</volume>
<issue>3</issue>
<fpage>181</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">7698094</pub-id>
</element-citation>
</ref>
<ref id="b195-cmped-10-2016-043">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plioplys</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Autism: electroencephalogram abnormalities and clinical improvement with valproic acid</article-title>
<source/>Arch Pediatr Adolesc Med
          <year>1994</year>
<volume>148</volume>
<issue>2</issue>
<fpage>220</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">8118547</pub-id>
</element-citation>
</ref>
<ref id="b196-cmped-10-2016-043">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Childs</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Valproic acid treatment of epilepsy in autistic twins</article-title>
<source/>J Neurosci Nurs
          <year>1997</year>
<volume>29</volume>
<issue>4</issue>
<fpage>244</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9307927</pub-id>
</element-citation>
</ref>
<ref id="b197-cmped-10-2016-043">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pressler</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Binnie</surname>
<given-names>CD</given-names>
</name>
</person-group>
<article-title>Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy</article-title>
<source/>J Pediatr
          <year>2005</year>
<volume>146</volume>
<issue>1</issue>
<fpage>112</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15644834</pub-id>
</element-citation>
</ref>
<ref id="b198-cmped-10-2016-043">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Besag</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Binnie</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effects of transitory cognitive impairment on psychosocial functioning of children with epilepsy: a therapeutic trial</article-title>
<source/>Dev Med Child Neurol
          <year>1993</year>
<volume>35</volume>
<issue>7</issue>
<fpage>574</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">9435773</pub-id>
</element-citation>
</ref>
<ref id="b199-cmped-10-2016-043">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ronen</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Secord</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosenbloom</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Can sodium valproate improve learning in children with epileptiform bursts but without clinical seizures?</article-title>
<source/>Dev Med Child Neurol
          <year>2000</year>
<volume>42</volume>
<issue>11</issue>
<fpage>751</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">11104347</pub-id>
</element-citation>
</ref>
<ref id="b200-cmped-10-2016-043">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahajan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bernal</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Panzer</surname>
<given-names>R</given-names>
</name>
<etal></etal>
<collab>Autism Speaks Autism Treatment Network Psychopharmacology C</collab>
</person-group>
<article-title>Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders</article-title>
<source/>Pediatrics
          <year>2012</year>
<volume>130</volume>
<issue>suppl 2</issue>
<fpage>S125</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">23118243</pub-id>
</element-citation>
</ref>
<ref id="b201-cmped-10-2016-043">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scahill</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>King</surname>
<given-names>BH</given-names>
</name>
<etal></etal>
</person-group>
<collab>Research Units on Pediatric Psychopharmacology Autism N</collab>
<article-title>Extended-release guanfacine for hyperactivity in children with autism spectrum disorder</article-title>
<source/>Am J Psychiatry
          <year>2015</year>
<volume>172</volume>
<issue>12</issue>
<fpage>1197</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">26315981</pub-id>
</element-citation>
</ref>
<ref id="b202-cmped-10-2016-043">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Aman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2006</year>
<volume>45</volume>
<issue>10</issue>
<fpage>1196</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="pmid">17003665</pub-id>
</element-citation>
</ref>
<ref id="b203-cmped-10-2016-043">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harfterkamp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buitelaar</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Minderaa</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>van de Loo-Neus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van der Gaag</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2014</year>
<volume>24</volume>
<issue>9</issue>
<fpage>481</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">25369243</pub-id>
</element-citation>
</ref>
<ref id="b204-cmped-10-2016-043">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harfterkamp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van de Loo-Neus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Minderaa</surname>
<given-names>RB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2012</year>
<volume>51</volume>
<issue>7</issue>
<fpage>733</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">22721596</pub-id>
</element-citation>
</ref>
<ref id="b205-cmped-10-2016-043">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Meer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Harfterkamp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van de Loo-Neus</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms</article-title>
<source/>J Clin Psychopharmacol
          <year>2013</year>
<volume>33</volume>
<issue>6</issue>
<fpage>824</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24018545</pub-id>
</element-citation>
</ref>
<ref id="b206-cmped-10-2016-043">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Jaen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fernandez-Mayoralas</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Calleja-Perez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Munoz-Jareno</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>Diaz</given-names>
</name>
<name>
<surname>Mdel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lopez-Arribas</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study</article-title>
<source/>J Atten Disord
          <year>2013</year>
<volume>17</volume>
<issue>6</issue>
<fpage>497</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="pmid">22366240</pub-id>
</element-citation>
</ref>
<ref id="b207-cmped-10-2016-043">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harfterkamp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buitelaar</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Minderaa</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>van de Loo-Neus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van der Gaag</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2013</year>
<volume>23</volume>
<issue>3</issue>
<fpage>194</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">23578015</pub-id>
</element-citation>
</ref>
<ref id="b208-cmped-10-2016-043">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>An update on pharmacotherapy for autism spectrum disorder in children and adolescents</article-title>
<source/>Curr Opin Psychiatry
          <year>2015</year>
<volume>28</volume>
<issue>2</issue>
<fpage>91</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">25602248</pub-id>
</element-citation>
</ref>
<ref id="b209-cmped-10-2016-043">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correll</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Manu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Olshanskiy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents</article-title>
<source/>JAMA
          <year>2009</year>
<volume>302</volume>
<issue>16</issue>
<fpage>1765</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">19861668</pub-id>
</element-citation>
</ref>
<ref id="b210-cmped-10-2016-043">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wink</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Early</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2014</year>
<volume>24</volume>
<issue>2</issue>
<fpage>78</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">24564519</pub-id>
</element-citation>
</ref>
<ref id="b211-cmped-10-2016-043">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobo</surname>
<given-names>WV</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>WO</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antipsychotics and the risk of type 2 diabetes mellitus in children and youth</article-title>
<source/>JAMA Psychiatry
          <year>2013</year>
<volume>70</volume>
<issue>10</issue>
<fpage>1067</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">23965896</pub-id>
</element-citation>
</ref>
<ref id="b212-cmped-10-2016-043">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correll</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2007</year>
<volume>17</volume>
<issue>5</issue>
<fpage>647</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">17979584</pub-id>
</element-citation>
</ref>
<ref id="b213-cmped-10-2016-043">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brignell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Randall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silove</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hazell</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)</article-title>
<source/>Cochrane Database Syst Rev
          <year>2013</year>
<volume>8</volume>
<fpage>CD004677</fpage>
<pub-id pub-id-type="pmid">23959778</pub-id>
</element-citation>
</ref>
<ref id="b214-cmped-10-2016-043">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Drugmakers dance with autism</article-title>
<source/>Nat Biotechnol
          <year>2010</year>
<volume>28</volume>
<issue>8</issue>
<fpage>772</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">20697394</pub-id>
</element-citation>
</ref>
<ref id="b215-cmped-10-2016-043">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erickson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Veenstra-Vanderweele</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<issue>4</issue>
<fpage>958</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">24272415</pub-id>
</element-citation>
</ref>
<ref id="b216-cmped-10-2016-043">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemonnier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Degrez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Phelep</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomised controlled trial of bumetanide in the treatment of autism in children</article-title>
<source/>Transl Psychiatry
          <year>2012</year>
<volume>2</volume>
<fpage>e202</fpage>
<pub-id pub-id-type="pmid">23233021</pub-id>
</element-citation>
</ref>
<ref id="b217-cmped-10-2016-043">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Aimonovitch</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders</article-title>
<source/>J Child Neurol
          <year>2002</year>
<volume>17</volume>
<issue>11</issue>
<fpage>833</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">12585724</pub-id>
</element-citation>
</ref>
<ref id="b218-cmped-10-2016-043">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erickson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Early</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stigler</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Mullett</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>An open-label naturalistic pilot study of acamprosate in youth with autistic disorder</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2011</year>
<volume>21</volume>
<issue>6</issue>
<fpage>565</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22136091</pub-id>
</element-citation>
</ref>
<ref id="b219-cmped-10-2016-043">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erickson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Early</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brief report: pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<issue>4</issue>
<fpage>981</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24052275</pub-id>
</element-citation>
</ref>
<ref id="b220-cmped-10-2016-043">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2001</year>
<volume>40</volume>
<issue>6</issue>
<fpage>658</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">11392343</pub-id>
</element-citation>
</ref>
<ref id="b221-cmped-10-2016-043">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammadi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Yadegari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hassanzadeh</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study</article-title>
<source/>Clin Neuropharmacol
          <year>2013</year>
<volume>36</volume>
<issue>6</issue>
<fpage>179</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">24201232</pub-id>
</element-citation>
</ref>
<ref id="b222-cmped-10-2016-043">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rotge</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Choucha</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Resistant catatonia in a high-functioning autism spectrum disorder patient successfully treated with amantadine</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2015</year>
<volume>25</volume>
<issue>9</issue>
<fpage>726</fpage>
<pub-id pub-id-type="pmid">26258287</pub-id>
</element-citation>
</ref>
<ref id="b223-cmped-10-2016-043">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardan</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Libove</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized controlled pilot trial of oral N-acetylcysteine in children with autism</article-title>
<source/>Biol Psychiatry
          <year>2012</year>
<volume>71</volume>
<issue>11</issue>
<fpage>956</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">22342106</pub-id>
</element-citation>
</ref>
<ref id="b224-cmped-10-2016-043">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moghimi-Sarani</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders</article-title>
<source/>BMC Psychiatry
          <year>2013</year>
<volume>13</volume>
<issue>1</issue>
<fpage>196</fpage>
<pub-id pub-id-type="pmid">23886027</pub-id>
</element-citation>
</ref>
<ref id="b225-cmped-10-2016-043">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van</surname>
<given-names>IMH</given-names>
</name>
<name>
<surname>Bakermans-Kranenburg</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>The role of oxytocin in parenting and as augmentative pharmacotherapy; critical issues and bold conjectures</article-title>
<source/>J Neuroendocrinol
          <year>2016</year>
<comment>In press</comment>
</element-citation>
</ref>
<ref id="b226-cmped-10-2016-043">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>McGrew</surname>
<given-names>SG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>8</issue>
<fpage>1729</fpage>
<lpage>37</lpage>
<comment>author reply 1738</comment>
<pub-id pub-id-type="pmid">22160300</pub-id>
</element-citation>
</ref>
<ref id="b227-cmped-10-2016-043">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Foldes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Kronk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wiggs</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Behavioral parent training to address sleep disturbances in young children with autism spectrum disorder: a pilot trial</article-title>
<source/>Sleep Med
          <year>2013</year>
<volume>14</volume>
<issue>10</issue>
<fpage>995</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="pmid">23993773</pub-id>
</element-citation>
</ref>
<ref id="b228-cmped-10-2016-043">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Byars</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep Committee of the Autism Treatment N. A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders</article-title>
<source/>Pediatrics
          <year>2012</year>
<volume>130</volume>
<issue>suppl 2</issue>
<fpage>S106</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">23118242</pub-id>
</element-citation>
</ref>
<ref id="b229-cmped-10-2016-043">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackmer</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Management of sleep disorders in children with neurodevelopmental disorders: a review</article-title>
<source/>Pharmacotherapy
          <year>2016</year>
<volume>36</volume>
<issue>1</issue>
<fpage>84</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">26799351</pub-id>
</element-citation>
</ref>
<ref id="b230-cmped-10-2016-043">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortesi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giannotti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sebastiani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Panunzi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial</article-title>
<source/>J Sleep Res
          <year>2012</year>
<volume>21</volume>
<issue>6</issue>
<fpage>700</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22616853</pub-id>
</element-citation>
</ref>
<ref id="b231-cmped-10-2016-043">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Sleep disorders, epilepsy, and autism</article-title>
<source/>Ment Retard Dev Disabil Res Rev
          <year>2004</year>
<volume>10</volume>
<issue>2</issue>
<fpage>122</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15362168</pub-id>
</element-citation>
</ref>
<ref id="b232-cmped-10-2016-043">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ming</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Use of clonidine in children with autism spectrum disorders</article-title>
<source/>Brain Dev
          <year>2008</year>
<volume>30</volume>
<issue>7</issue>
<fpage>454</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">18280681</pub-id>
</element-citation>
</ref>
<ref id="b233-cmped-10-2016-043">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaselskis</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>EH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Fletcher</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Leventhal</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Clonidine treatment of hyperactive and impulsive children with autistic disorder</article-title>
<source/>J Clin Psychopharmacol
          <year>1992</year>
<volume>12</volume>
<issue>5</issue>
<fpage>322</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">1479049</pub-id>
</element-citation>
</ref>
<ref id="b234-cmped-10-2016-043">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingrassia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turk</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders – a case series</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2005</year>
<volume>14</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">15756514</pub-id>
</element-citation>
</ref>
<ref id="b235-cmped-10-2016-043">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fankhauser</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Karumanchi</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>German</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karumanchi</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism</article-title>
<source/>J Clin Psychiatry
          <year>1992</year>
<volume>53</volume>
<issue>3</issue>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">1548248</pub-id>
</element-citation>
</ref>
<ref id="b236-cmped-10-2016-043">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Blau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>EV</given-names>
</name>
</person-group>
<article-title>A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome</article-title>
<source/>Dev Med Child Neurol
          <year>2008</year>
<volume>50</volume>
<issue>5</issue>
<fpage>346</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">18355335</pub-id>
</element-citation>
</ref>
<ref id="b237-cmped-10-2016-043">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hyland</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebral folate deficiency with developmental delay, autism, and response to folinic acid</article-title>
<source/>Neurology
          <year>2005</year>
<volume>64</volume>
<issue>6</issue>
<fpage>1088</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">15781839</pub-id>
</element-citation>
</ref>
<ref id="b238-cmped-10-2016-043">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism</article-title>
<source/>Am J Clin Nutr
          <year>2009</year>
<volume>89</volume>
<issue>1</issue>
<fpage>425</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">19056591</pub-id>
</element-citation>
</ref>
<ref id="b239-cmped-10-2016-043">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status</article-title>
<source/>Autism Res Treat
          <year>2013</year>
<volume>2013</volume>
<fpage>609705</fpage>
<pub-id pub-id-type="pmid">24224089</pub-id>
</element-citation>
</ref>
<ref id="b240-cmped-10-2016-043">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertoglio</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jill James</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deprey</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brule</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hendren</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism</article-title>
<source/>J Altern Complement Med
          <year>2010</year>
<volume>16</volume>
<issue>5</issue>
<fpage>555</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">20804367</pub-id>
</element-citation>
</ref>
<ref id="b241-cmped-10-2016-043">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hendren</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Widjaja</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lawton</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rosenblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bent</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Randomized, placebo-controlled trial of methyl B12 for children with autism</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2016</year>
<comment>In press</comment>
</element-citation>
</ref>
<ref id="b242-cmped-10-2016-043">
<label>242</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danfors</surname>
<given-names>T</given-names>
</name>
<name>
<surname>von Knorring</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Hartvig</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study</article-title>
<source/>J Clin Psychopharmacol
          <year>2005</year>
<volume>25</volume>
<issue>5</issue>
<fpage>485</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">16160627</pub-id>
</element-citation>
</ref>
<ref id="b243-cmped-10-2016-043">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaiman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huffman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Masaki</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2013</year>
<volume>23</volume>
<issue>5</issue>
<fpage>320</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23782126</pub-id>
</element-citation>
</ref>
<ref id="b244-cmped-10-2016-043">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nareuse</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hayash</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Takesada</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Therapeutic effect of tetrahydrobiopterin in infantile autism</article-title>
<source/>Pron Japan Acad
          <year>1987</year>
<volume>63</volume>
<fpage>231</fpage>
<lpage>3</lpage>
</element-citation>
</ref>
<ref id="b245-cmped-10-2016-043">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pastural</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism</article-title>
<source/>Prostaglandins Leukot Essent Fatty Acids
          <year>2009</year>
<volume>81</volume>
<issue>4</issue>
<fpage>253</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">19608392</pub-id>
</element-citation>
</ref>
<ref id="b246-cmped-10-2016-043">
<label>246</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gargus</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Imtiaz</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Mitochondrial energy-deficient endophenotype in autism</article-title>
<source/>Am J Biochem Biotech
          <year>2008</year>
<volume>4</volume>
<issue>2</issue>
<fpage>198</fpage>
<lpage>207</lpage>
</element-citation>
</ref>
<ref id="b247-cmped-10-2016-043">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poling</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Shoffner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Developmental regression and mitochondrial dysfunction in a child with autism</article-title>
<source/>J Child Neurol
          <year>2006</year>
<volume>21</volume>
<issue>2</issue>
<fpage>170</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">16566887</pub-id>
</element-citation>
</ref>
<ref id="b248-cmped-10-2016-043">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezugha</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Goldenthal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valencia</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Legido</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>5q14.3 deletion manifesting as mitochondrial disease and autism: case report</article-title>
<source/>J Child Neurol
          <year>2010</year>
<volume>25</volume>
<issue>10</issue>
<fpage>1232</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">20179003</pub-id>
</element-citation>
</ref>
<ref id="b249-cmped-10-2016-043">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders</article-title>
<source/>Med Sci Monit
          <year>2011</year>
<volume>17</volume>
<issue>6</issue>
<fpage>I15</fpage>
<lpage>23</lpage>
</element-citation>
</ref>
<ref id="b250-cmped-10-2016-043">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahmy</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>El-hamamsy</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Badary</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>l-Carnitine supplementation improves the behavioral symptoms in autistic children</article-title>
<source/>Res Autism Spectr Disord
          <year>2013</year>
<volume>7</volume>
<issue>1</issue>
<fpage>159</fpage>
<lpage>66</lpage>
</element-citation>
</ref>
<ref id="b251-cmped-10-2016-043">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Audhya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McDonough-Means</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of a vitamin/mineral supplement on children and adults with autism</article-title>
<source/>BMC Pediatr
          <year>2011</year>
<volume>11</volume>
<fpage>111</fpage>
<pub-id pub-id-type="pmid">22151477</pub-id>
</element-citation>
</ref>
<ref id="b252-cmped-10-2016-043">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>EA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sulforaphane treatment of autism spectrum disorder (ASD)</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<issue>43</issue>
<fpage>15550</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">25313065</pub-id>
</element-citation>
</ref>
<ref id="b253-cmped-10-2016-043">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taliou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zintzaras</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lykouras</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders</article-title>
<source/>Clin Ther
          <year>2013</year>
<volume>35</volume>
<issue>5</issue>
<fpage>592</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="pmid">23688534</pub-id>
</element-citation>
</ref>
<ref id="b254-cmped-10-2016-043">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolske</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Spollen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lancashire</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tolbert</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A preliminary trial of ascorbic acid as supplemental therapy for autism</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>1993</year>
<volume>17</volume>
<issue>5</issue>
<fpage>765</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">8255984</pub-id>
</element-citation>
</ref>
<ref id="b255-cmped-10-2016-043">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Treatments for mitochondrial dysfunction associated with autism spectrum disorders</article-title>
<source/>J Ped Biochem
          <year>2012</year>
<volume>2</volume>
<issue>4</issue>
<fpage>241</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="b256-cmped-10-2016-043">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder</article-title>
<source/>J Altern Complement Med
          <year>2004</year>
<volume>10</volume>
<issue>6</issue>
<fpage>1033</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15673999</pub-id>
</element-citation>
</ref>
<ref id="b257-cmped-10-2016-043">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gvozdjakova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kucharska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ostatnikova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Babinska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakladal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>FL</given-names>
</name>
</person-group>
<article-title>Ubiquinol improves symptoms in children with autism</article-title>
<source/>Oxid Med Cell Longev
          <year>2014</year>
<volume>2014</volume>
<fpage>798957</fpage>
<pub-id pub-id-type="pmid">24707344</pub-id>
</element-citation>
</ref>
<ref id="b258-cmped-10-2016-043">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aneja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tierney</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Autism: the role of cholesterol in treatment</article-title>
<source/>Int Rev Psychiatry
          <year>2008</year>
<volume>20</volume>
<issue>2</issue>
<fpage>165</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">18386207</pub-id>
</element-citation>
</ref>
<ref id="b259-cmped-10-2016-043">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Edelson</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Improvements in children with autism treated with intravenous gamma globulin</article-title>
<source/>J Nutr Environ Med
          <year>2005</year>
<volume>15</volume>
<issue>4</issue>
<fpage>169</fpage>
<lpage>76</lpage>
</element-citation>
</ref>
<ref id="b260-cmped-10-2016-043">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Samra</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin</article-title>
<source/>J Clin Immunol
          <year>2010</year>
<volume>30</volume>
<issue>suppl 1</issue>
<fpage>S90</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">20393790</pub-id>
</element-citation>
</ref>
<ref id="b261-cmped-10-2016-043">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niederhofer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Staffen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mair</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder</article-title>
<source/>Neuropsychopharmacology
          <year>2003</year>
<volume>28</volume>
<issue>5</issue>
<fpage>1014</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">12700706</pub-id>
</element-citation>
</ref>
<ref id="b262-cmped-10-2016-043">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DelGiudice-Asch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schmeidler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cunningham-Rundles</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hollander</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism</article-title>
<source/>J Autism Dev Disord
          <year>1999</year>
<volume>29</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">10382136</pub-id>
</element-citation>
</ref>
<ref id="b263-cmped-10-2016-043">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plioplys</surname>
<given-names>AV</given-names>
</name>
</person-group>
<article-title>Intravenous immunoglobulin treatment of children with autism</article-title>
<source/>J Child Neurol
          <year>1998</year>
<volume>13</volume>
<issue>2</issue>
<fpage>79</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">9512308</pub-id>
</element-citation>
</ref>
<ref id="b264-cmped-10-2016-043">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlmutter</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Leitman</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood</article-title>
<source/>Lancet
          <year>1999</year>
<volume>354</volume>
<issue>9185</issue>
<fpage>1153</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">10513708</pub-id>
</element-citation>
</ref>
<ref id="b265-cmped-10-2016-043">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlmutter</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Castellanos</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A case of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections</article-title>
<source/>Am J Psychiatry
          <year>1998</year>
<volume>155</volume>
<issue>11</issue>
<fpage>1592</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9812123</pub-id>
</element-citation>
</ref>
<ref id="b266-cmped-10-2016-043">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovacevic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections</article-title>
<source/>J Child Adolesc Psychopharmacol
          <year>2015</year>
<volume>25</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">25658609</pub-id>
</element-citation>
</ref>
<ref id="b267-cmped-10-2016-043">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Barstow</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Enriquez</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Ranger-Moore</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ostrem</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study</article-title>
<source/>J Autism Dev Disord
          <year>2006</year>
<volume>36</volume>
<issue>8</issue>
<fpage>1053</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">16845577</pub-id>
</element-citation>
</ref>
<ref id="b268-cmped-10-2016-043">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Handen</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>RL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder</article-title>
<source/>J Autism Dev Disord
          <year>2009</year>
<volume>39</volume>
<issue>5</issue>
<fpage>796</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">19148734</pub-id>
</element-citation>
</ref>
<ref id="b269-cmped-10-2016-043">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asadabadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>Psychopharmacology
          <year>2013</year>
<volume>225</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22782459</pub-id>
</element-citation>
</ref>
<ref id="b270-cmped-10-2016-043">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kominsky</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children</article-title>
<source/>Pediatr Neurol
          <year>2007</year>
<volume>36</volume>
<issue>6</issue>
<fpage>361</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">17560496</pub-id>
</element-citation>
</ref>
<ref id="b271-cmped-10-2016-043">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fallah</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2010</year>
<volume>34</volume>
<issue>1</issue>
<fpage>32</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">19772883</pub-id>
</element-citation>
</ref>
<ref id="b272-cmped-10-2016-043">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chez</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Loeffel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Field-Chez</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pulse high dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism</article-title>
<source/>Ann Neurol
          <year>1998</year>
<volume>44</volume>
<fpage>539</fpage>
</element-citation>
</ref>
<ref id="b273-cmped-10-2016-043">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Shankardass</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McAnulty</surname>
<given-names>GB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Corticosteroid therapy in regressive autism: a retrospective study of effects on the frequency modulated auditory evoked response (FMAER), language, and behavior</article-title>
<source/>BMC Neurol
          <year>2014</year>
<volume>14</volume>
<fpage>70</fpage>
<pub-id pub-id-type="pmid">24885033</pub-id>
</element-citation>
</ref>
<ref id="b274-cmped-10-2016-043">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mumper</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study</article-title>
<source/>BMC Pediatr
          <year>2007</year>
<volume>7</volume>
<fpage>36</fpage>
<pub-id pub-id-type="pmid">18005455</pub-id>
</element-citation>
</ref>
<ref id="b275-cmped-10-2016-043">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>MacFabe</surname>
<given-names>DF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Approaches to studying and manipulating the enteric microbiome to improve autism symptoms</article-title>
<source/>Microb Ecol Health Dis
          <year>2015</year>
<volume>26</volume>
<fpage>26878</fpage>
<pub-id pub-id-type="pmid">25956237</pub-id>
</element-citation>
</ref>
<ref id="b276-cmped-10-2016-043">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buie</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Gastroesophageal reflux in children with autism: how do children present and can one test these children?</article-title>
<source/>J Pediatr Gastroenterol Nutr
          <year>2005</year>
<volume>41</volume>
<issue>4</issue>
<fpage>505</fpage>
</element-citation>
</ref>
<ref id="b277-cmped-10-2016-043">
<label>277</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elder</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shuster</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Theriaque</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sherrill</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial</article-title>
<source/>J Autism Dev Disord
          <year>2006</year>
<volume>36</volume>
<issue>3</issue>
<fpage>413</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">16555138</pub-id>
</element-citation>
</ref>
<ref id="b278-cmped-10-2016-043">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knivsberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Reichelt</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Hoien</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nodland</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A randomised, controlled study of dietary intervention in autistic syndromes</article-title>
<source/>Nutr Neurosci
          <year>2002</year>
<volume>5</volume>
<issue>4</issue>
<fpage>251</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">12168688</pub-id>
</element-citation>
</ref>
<ref id="b279-cmped-10-2016-043">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haracopos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Knivsberg</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders</article-title>
<source/>Nutr Neurosci
          <year>2010</year>
<volume>13</volume>
<issue>2</issue>
<fpage>87</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">20406576</pub-id>
</element-citation>
</ref>
<ref id="b280-cmped-10-2016-043">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pennesi</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Effectiveness of the gluten-free, casein-free diet for children diagnosed with autism spectrum disorder: based on parental report</article-title>
<source/>Nutr Neurosci
          <year>2012</year>
<volume>15</volume>
<issue>2</issue>
<fpage>85</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">22564339</pub-id>
</element-citation>
</ref>
<ref id="b281-cmped-10-2016-043">
<label>281</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kossoff</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HS</given-names>
</name>
</person-group>
<article-title>Dietary therapies for epilepsy</article-title>
<source/>Biomed J
          <year>2013</year>
<volume>36</volume>
<issue>1</issue>
<fpage>2</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23515147</pub-id>
</element-citation>
</ref>
<ref id="b282-cmped-10-2016-043">
<label>282</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brudnak</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rimland</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kerry</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enzyme-based therapy for autism spectrum disorders – is it worth another look?</article-title>
<source/>Med Hypotheses
          <year>2002</year>
<volume>58</volume>
<issue>5</issue>
<fpage>422</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">12056881</pub-id>
</element-citation>
</ref>
<ref id="b283-cmped-10-2016-043">
<label>283</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munasinghe</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Oliff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wray</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial</article-title>
<source/>J Autism Dev Disord
          <year>2010</year>
<volume>40</volume>
<issue>9</issue>
<fpage>1131</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">20204691</pub-id>
</element-citation>
</ref>
<ref id="b284-cmped-10-2016-043">
<label>284</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saad</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eltayeb</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Mohamad</surname>
<given-names>IL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized, placebo-controlled trial of digestive enzymes in children with autism spectrum disorders</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2015</year>
<volume>13</volume>
<issue>2</issue>
<fpage>188</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">26243847</pub-id>
</element-citation>
</ref>
<ref id="b285-cmped-10-2016-043">
<label>285</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaluzna-Czaplinska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blaszczyk</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The level of arabinitol in autistic children after probiotic therapy</article-title>
<source/>Nutrition
          <year>2012</year>
<volume>28</volume>
<issue>2</issue>
<fpage>124</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">22079796</pub-id>
</element-citation>
</ref>
<ref id="b286-cmped-10-2016-043">
<label>286</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parracho</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Knott</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bosscher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kleerebezem</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders</article-title>
<source/>Int J Probiotics Prebiotics
          <year>2010</year>
<volume>5</volume>
<issue>2</issue>
<fpage>69</fpage>
<lpage>74</lpage>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>